American Neurological Association (ANA)



SEQ CHAPTER \h \r 1EMORY UNIVERSITY SCHOOL OF MEDICINE Revised: 4/20/2020Emory Format1.Name: Raymond Edward Faught, Jr.52324006985002.Office Address:Emory Department of NeurologyBrain Health Center 29212 Executive Park Drive NE Atlanta, GA 30329Telephone: 404-778-3444; Cellular 404-550-2634 Facsimile: 404-778-5150 Electronic mail address: rfaught@emory.edu3.Birth Place:Jasper, Alabama, USA4.Citizenship:United States of America5.Current Titles and Affiliations:Professor of Neurology, Emory University School of Medicine, 2009-Director, Emory Epilepsy Program, 2013-Voluntary Professor of Neurology, University of Alabama School of Medicine, 2010-Active Staff Member: Emory University Hospital, Emory University Hospital Midtown, Grady Memorial Hospital, Emory St. Joseph’s Hospital, Children’s Healthcare of Atlanta 6. Previous academic and professional appointments1978-79Assistant Professor of NeurologyUniversity of Virginia School of MedicineCharlottesville, Virginia1980-1983Assistant Professor of NeurologyUniversity of Alabama School of MedicineBirmingham, Alabama1983–1996Associate Professor of Neurology (Tenured from 1986)University of Alabama School of Medicine1996-2009Professor of Neurology (Tenured)University of Alabama School of Medicine 7. Previous Administrative and/or Clinical Appointments (chronological order;):Staff Physician, Department of Veterans’ Affairs Medical Center Birmingham, 1980-2009. Established Seizure Monitoring Unit, epilepsy clinics, served as site investigator for two large Cooperative Studies trialsDirector, EEG Laboratories., Univ.of Alabama Hospital, 1981-2009. Established 24/7 ICU EEG/videomonitoring, expanded technologist numbers and increased registration percentage, Developed formal curriculum and lecture series on EEG for residents.Director, UAB Adult Seizure Clinic, 1981 .Founder. Grew to become the UAB Epilepsy Center by vote of the University of Alabama Board of Trustees, Feb, 1986. Satellite clinics in 3 Alabama cities 1982-1998.Director, Residency Training Program in Neurology, UAB, 1983-1990. Increased size of residency program from 3 to 10. The program regained full certification by ACGME and residency inservice exam scores rose by 50 percentile points nationally.Director, University of Alabama at Birmingham Epilepsy Center, 1986-1996, 2001-2009. Achieved official designation as an interdisciplinary center from the University of Alabama Board of Trustess 1986, established programs including epilepsy clinics, inpatient seizure monitoring unit, epilepsy surgical treatment program, research programs in clinical pharmacology and neuroimaging, and designation as a Level 4 center by the National Association of Epilepsy Centers.Director, Clinical Pharmacology Research, UAB Epilepsy Center, 1987-2009. Established one of the largest antiepileptic drug clinical trials programs in the world beginning with an NIH Master Agreement (1987) for Phase I, II, III, and IV trials of antiepileptic drugs Assisted in conception of innovative trial designs for epilepsy sponsored by NIH, VA, and industry.Associate Director, Clinical Neurophysiology Residency Program, University of Alabama Medical Center, 1995-2009. Vice Chair, Department of Neurology, University of Alabama School of Medicine, 1996-2001, 2003-2009. Responsible for quality improvement, compliance, faculty development, and other tasks assigned by the Chair.Interim Chair, Department of Neurology, University of Alabama School of Medicine, August 2001-June 2003, and Jan 2008- Sept 2008. During 2001-2003, the faculty size increased, budget improved from deficit to surplus, NIH research funding ranking improved, resident inservice scores rose, and all residency positions were filled. Medical Director, Neurology Inpatient Services, University of Alabama. Hospital, 2007-2009. Responsible for quality improvement, stroke center certification, faculty schedules, liason with nursing and support staff, and weekly case presentation conference with all residents. Division Director, Division of Epilepsy, UAB, division established 2004, to 2009Scientist, UAB Comprehensive Neuroscience Center, 2008-2009Chief, Neurology Service, Emory University Hospital Midtown, March 2010-August 2013. Established continuous EEG-videomonitoring service for intensive care, transformed neurohospitalist staff to full-time Emory faculty, arranged for 24/7 coverage for neurological emergencies, obtained Primary Stroke Center certification.Associate Chief of Service, Emory University Department of Neurology, March 2010-August-2013 8. Licensures/BoardsNational Board of Medical Examiners, 1973, #126407Virginia State Board of Medical Examiners, 1974-1981, #0101024574, Alabama State Board of Medical Licensure 1980-2010, #9314 Georgia State Board of Medical Examiners, 2009-exp 8/31/2022, #63347NPI: 1497799134 9. Specialty Boards:Certified in Neurology, American Board. of Psychiatry and Neurology,1980, (permanent), #20539Certified, American Board of Clinical Neurophysiology (EEG)1982, (permanent) American Board of Psychiatry and Neurology, Certified in Clinical Neurophysiology, 1994 #307; Recertified, 2003. Education: 1964 Walker County High School, Jasper, Alabama1968 (Sep ‘64 - Jun ‘68) Harvard College, A.B. cum laude, Field of Concentration: Social Relations (psychology and sociology)Sep ‘68 - Jun ’69, Columbia University College of Physicians and Surgeons, First year of medical school. Sep ‘69 - May ‘72, Vanderbilt University School of Medicine, M.D.Postgraduate Training: 1972-1973 Intern, Straight MedicineUniversity of Virginia HospitalCharlottesville, VirginiaProgram Director: Edward Hook, M.D.1975-1977 Resident NeurologistUniversity of Virginia HospitalProgram Director: T. R. Johns II, M.D.`1977-1978 Chief Resident NeurologistUniversity of Virginia Hospital Program Director: T. R. Johns II, M.D.1979-1980 Research Associate (Fellowship, NIH funded)Comprehensive Epilepsy ProgramUniversity of Virginia School of MedicineCharlottesville, Virginia Program Directors: Fritz E. Dreifuss, M.D. and S.I. Lee, M.D. 11B. Miscellaneous Training and Skills Pharmacology research, cyclic AMP and seizures, Theodore Rall, PhD, U Va 1977-80 Infectious disease clerkship, Letterman Army Med. Ctr. San Francisco, summer 1970 Cardiology clerkship, Middlesex Hospital, Univ of London, summer 1971 Neurology clerkship, Yale University School of Medicine, fall 1971 Karyotyper, Laboratory of Medical Genetics, UAB, summer 1969 Surgical technician, Carraway Methodist Hospital, Birmingham, AL summer 1966 Lab technician, endocrinology, Peter Bent Brigham Hospital, Boston 1966-7 Crop surveyor, US Dept of Agriculture, summers 1964, 1965 Red Cross Senior Lifesaving Certification, 1964 Military and Government Service:Military Service- United States Army RanksSecond Lieutenant, Medical Service Corps, US Army Reserve, 1969-1973First Lieutenant, Medical Service Corps, US Army Reserve, 1973Captain, Medical Corps, Army of the U.S., 1973-1975 (Active Duty)Captain, Medical Corps, US Army Reserve, 1975-1982Major, Medical Corps, US Army Reserve, 1983-1990Lieutenant Colonel, Medical Corps, US Army Reserve, 1990-1999Colonel, Medical Corps, US Army Reserve, 1999-2006Colonel, United States Army (Retired), 2006-current United States Army Assignments (5 Extended Active Duty assignments 1970-2006)1969-73 Army Reserve, inactive during training programs1973-1974 Officer in Charge, U.S. Army Medical ClinicPittsburgh, PA (active duty)1974-1975 General Medical Officer, Kenner Army HospitalFort Lee, Virginia (active duty)1976-1980 Physician, 56tth Station Hospital, Richmond, VA, Army Reserve1980-83 Physician 3345th US Army Hospital, Birmingham, AL, Army Res.1983-93 Chief of Clinics, 3345th US Army Hosp., Birmingham, Jan- May, 1991 Staff Neurologist, Eisenhower Army Medical Ctr., Augusta, GA (active duty) (Operation Desert Storm)1993-96 Chief of Professional Services, 3345th USAH, BHM, Army Res.1996-99 Commander, 3345th US Army Hospital (1000 Bed) Birmingham, AL, Army Reserve. The 3345th USAH was an reserve hospital with a complete complement of physicians, nurses, technologists, and support personnel, equipped to deploy worldwide. In the Army, the Hospital Commander serves the dual functions of hospital administrator and chief of the medical staff, and is the top link in the chain of command for hospital personnel. 1999-2002 Chief of Professional Services, 1207th U.S. Army Hospital (Detachment 1) Birmingham. AL, Army Reserve.Responsible for continuing education and quality of medical care.July-Oct 2002 Neurologist, 405th Combat Support Hospital (Forward), Army Central Command, Kuwait (active duty) (Operation Enduring Freedom).As the only US military neurologist in the Middle East, I was responsible for neurological preparations for impending war in Iraq, as well as for neurological care for military personnel in the entire Middle East. Oct 2005-Jan 2006 Neurologist. Landstuhl Regional Medical Center, US Army Europe, Landstuhl, Germany (active duty) Triage officer: Responsible for evaluation, treatment, and disposition of military personnel evacuated from the Middle East with neurological problems. 2003-06 Command Surgeon, 81st Division (Regional Readiness Command). US Army Reserve. Responsible for medical readiness for all Army Reserve soldiers in 8 Southeastern states, and for coordination of all medical units in this region. Served as chief medical advisor to the Commanding General. (reserve + active)Reserve Overseas Assignments: Panama, Germany, El Salvador b. Veterans’ Administration Service1978-1979 Director, Neurology Service,Veterans’ Administration Medical Center, Salem, Virginia1980-2009 Staff Physician (Neurology), Birmingham Dept. of Veterans’ Affairs Medical Center, Birmingham, Alabama (usually 3/8 time)1982-2009 Director, EEG/Seizure Monitoring Laboratory, BirminghamCommittee Memberships (National/international) American Academy of Neurology Annual Meeting Abstract Reviewer, 1995 Treasurer and Executive Committee, Section of ClinicalNeurophysiology, 1992-1994 Breakfast Seminar Director, EEG in Status Epilepticus,1997, 1998American Board of Clinical NeurophysiologyAssociate Examiner, 1983-2000. Oral board examiner for EEG certification. (formerly Am Board of Qualification in EEG)American EEG Society Practice Committee, 1994-1997 American Epilepsy Society Neuropharmacology Platform Session Moderator, 1994 Task Force on New Drug Guidelines, 1994-1996 Clinical Pharmacology Task Force, 1997-2000 Annual Course Committee, 1996-1998 Felbamate Guidelines Committee 1997-1999 Co-Director, Antiepileptic Therapy Symposium, 2000-2002 Antiepileptic Drug Guidelines Committee, 2000-04 and 2010-16 Corporate Advisory Committee, 2007-2012 Chair, Corporate Advisory Committee, 2009-2012 Chair, Treatments Committee, 2010-2013 Council on Clinical Activities, 2010-2015 Chair, Q-PULSE Task Force 2013-2015 (survey instrument) Faculty, AES Webinar Series-Epilepsy Subspecialty Bd Rev (2016-17) Ad Hoc Work Group-AES response to FDA on cannabinoids, 2019Centers for Disease ControlGrant review panel for Special Interest Proposals SIP20-006 “Integrated Use of Community Health Workers with Medical Professionals in Epileps” and 20-007 “Examining the Burden of Epilepsy with Underutilized Large Databases”, 2020 Dept of Health and Human Svcs- Ctr. for Medicare and Medicaid Svcs. Medicare Evidence Development & Coverage Advisory Committee2012-2015. Advised CMMS on whether certain medical services should be covered by Medicare.Department of Veterans’ Affairs Research Service Member, Merit Review Board in Neurobiology (National), 1990-93. Reviewed and scored grants for VA research programs.VA Cooperative Study #428 “Treatment of Seizures in Elderly Patients”Executive Committee 1997-2003Drug Safety Monitoring - National Multicenter Trials Safety Monitor, STEPS Trial (gabapentin), 1996-1998 Safety Monitoring Board, Intravenous Depacon Trial, 1999-20 Chair, International Data Monitoring Board, perampanel, (2008-13) Steering Committee, Phase IV, Visual effects of vigabatrin (2008-2016) Chair, Data Monitoring Committee, SK LifeScience, cenobamate (2013-21 Data/Safety Mon. Comm., SAGE, refractory status epilepticus, 2015-17Epilepsy Foundation of AmericaNational Professional Advisory Board, 1992-1996 (elected term asSoutheast Regional Representative)Food and Drug Admknistration. Advisory Committee on vigabatrin for epilepsy, Aug 7-9, 2009, Washington, DCHuman Epilepsy Project, NYU/NIH/Epilepsy Foundation (sponsors)Pharmacology Core Committee, 2010-currentInternational League Against Epilepsy Chair, Task Force on Seizures in the Elderly 2017-2021 Member, Task Force on Evidence-Based Surgical Treatment, 2017-2021 Member, Medical Therapy Commission, 2017-2021International Epilepsy Consortium Executive Board, 1998-2005National Institutes of Health Chairman, Data Safety Monitoring Board, Epilepsy andSleep Apnea project, 2003-2006 (Beth Malow, Vanderbilt, PI)Site PI, NINDS Master Agreement for the Evaluation of Antiepileptic Drugs, Phases I-IV, contracts varied, 1987-1999.Postmarketing Antiepileptic Drug Survey Group, 2002-2010Committee Memberships (Regional and State) Southern EEG Society (Now Southern Epilepsy and EEG Society)President, 1989-1990Board of Directors, 1986-2005Program Chairman, 1992-1997Secretary-Treasurer, 1997-2004President, Alabama Council on Epilepsy (Epilepsy Foundation affiliate), 1988-1989Chairman, Professional Advisory Board, Alabama Council on Epilepsy,1983-1988 and 1989-1991 (Epilepsy Foundation affiliate)Epilepsy Foundation of N. and Central Al. (formerl AL Council on Epilepsy) Board of Directors, 1983-2009.Epilepsy Foundation of Alabama, Professional Advisory Board, 2009Epilepsy Foundation of Georgia, Professional Advisory Board, 2012- Committee Memberships (Institutional)Clinical Council, Univ. of Alabama Hosp., 1995-2001 and 2003-2007Chairman, Internal Advisory Committee, UAB Alzheimer’s Disease Research Center, 2001-2004UA Health System Charity Care Committee, 2003-2006UAB Clinical Research Advisory Group, 2002-2003UAB Office of Clinical Research, Steering Committee 1998-2001UASOM Faculty Council (promotions and tenure) 1998-2000UAB Faculty Senate, elected term 1995-1997UAB Faculty Senate, Governance and Operations Comm., 1995-1997 Quality Assurance Committee, University of Alabama Hosp., 1984-1991Associate Director, UAB Sleep/Wake Disorders Center, 1983-1987Quality Assurance Committee, Birmingham VA Med. Ctr, 1983-1988UAB Managed Care Committee, 1995 - 1997Kirklin Clinic Research Committee, 1995 -1998General Endowment Fund Grant Review Committee 1998 - 2005Dean’s Task Force on Patient-Oriented Research, 1997-1998UAB Department of Neurology Long-Range Planning Committee(Chairman), 1995-1997 and Practice Comm. Chairman, 1997-2001.UAB Continuing Medical Education Committee, 1995-1998 Univ. of Alabama Health System, Credentials Committee, 2002-2009 Emory Univ. Dept of Neurology, Education Committee Emory Univ. Dept of Neurology, Program Directors’ Committee Emory Univ. Hosp. Midtown, Medical Executive Committee, 2010-13 Emory Univ. Hospital Midtown, Credentials Committee, 2010-13Consultancies:2015-2020: Biogen, Eisai, UCB Pharma, SK Life Science, Neurelis, SupernusEditorships and Editorial Boards: Annals of Neurology, editorial board, 2019-Epilepsy Currents (Official journal of the American Epilepsy Society) Contributing Editor 2001–2006, Associate Editor (Clinical) 2015-2023Continuum. (Am. Acad. of Neurol/ CME Journal), 2001-2004.American Journal of Clinical Neurology, 2009-2012Editor, The Year in Neurology 1994, Oxford: Clinical Publishing, 2005Associate Editor, Frontiers in Neurology, 2010- 201416. Manuscript reviewer:Ad Hoc Reviewer for Neurology, Lancet, Lancet Neurology, Epilepsy and Behavior, Epilepsia, Annals of Neurology, Acta Neurologica Scandinavica, Archives of Neurology, Epilepsy Research, Clinical Drug Investigation, Epilepsy and Behavior, Drugs, Drugs and Aging, Frontiers in Neurology,Journal of Neuroscience Methods, Stroke, Am. J. Internal Medicine, Veterans Admin. Research Service, United States Pharmacopeia Convention, Journal of Clinical Neurophysiology, , Expert Opinion on Investigational Drugs 2017-20: Annals of Neurology, Neurology, Epilepsia, Epilepsy and Behavior, Epilepsy Research, Acta Neurologica Scandinavica, CNS Drugs, Seizure, Neuropharmacology, Drugs and Agings Honors and Awards: Fellow of the American Academy of Neurology, 1988 Fellow of the American Neurological Association; Elected Member, 1995 Fellow of the American Clinical Neurophysiology Society, 1996Fellow of the American Epilepsy Society (Inaugural Class, 2016)Platinum Provider Award, Emory Healthcare, for ranking in the top 10% nationwide in Press-Gainey survey of patient approval ratings for neurology, 2018Keynote Speaker, Residents’ Research Day, Univ. of Nebraska, 2017Hans Berger Lecturer Award, Medical College of Virginia, 2005Certificate of Appreciation, Governor of Alabama, for service to the Childrens’ Rehabilitation Service Epilepsy Clinics, 1980-2000National Volunteer Achievement Award, Epilepsy Foundation, 1985This was a single national award. Award was for establishing a system of epilepsy clinics for the State of Alabama.The Charles R.Walston Humanitarian Service Award of the Alabama Council on Epilepsy, 1986 (Renamed the “Edward Faught Award” in 2001, of the Epilepsy Foundation of North and Central Alabama)Listing in Best Doctors in America, yearly 1995-2019Best Doctors Southeast, 1996-1997 (1st ed.), Best Doctors in Birmingham, Birmingham Magazine, 2003-2009.Harvard College Dean’s List, 1964-68Eagle Scout Award, Boy Scouts of America, 1963 Military Awards:Army Commendation Medal, 1988 Cold War supportArmy Commendation Medal, 1991 Operation Desert StormArmy Achievement Medal, 2006 Triage neurologist for evacuees from the Middle East, Landstuhl Regional Medical Center, Germany Physical Fitness Excellence Badge; 1996-2006, perfect score in 2000Joint Meritorious Unit Award, 1996, U.S. Army as Commander of the 3345th US Army Hospital, for service during the Atlanta OlympicsGlobal War on Terrorism Expeditionary Medal, U.S. Army, 2002. Service with the 405th Combat Support Hospital, KuwaitMeritorious Service Medal, United States Army, 2006 Service as Commander, 3345th United States Army HospitalLegion of Merit, United States of America, 2006 . Career award, and service as Command Surgeon, 81ST Division (RSC)- US Army Reserve, for the southeastern US. (8 states)18.Society Memberships:Fellow, American Neurological AssociationFellow, American Academy of Neurology (<8% of membership)Fellow, American Clinical Neurophysiology SocietyFellow, American Epilepsy Society (<5% of membership)Southern Epilepsy and EEG SocietyGeorgia Neurological anization of National or International Conferences:Member: Annual Course Committee, American Epilepsy Society, 1996-98.Sessions as chair:Antiepileptic Therapy Symposium, Am. Epilepsy Society, 2002, 2003 American Academy of Neurology, Breakfast Seminar Course Director, “EEG in Status Epilepticus”, 1997 and1998Director,Quality of Life Advisory Board, UCB Pharma, 2012, London, UKDirector, Rational Polytherapy, satellite symposium to International Epilepsy Congress, GSK, Montreal, Canada, 2013Chair, Perampanel/generalized seizures board, Eisai, Jersey City, NJ, 2015Moderator and speaker, symposium “Treatment Gaps in Epilepsy”, 33rd International Epilepsy Congress, Bangkok, Thailand, 201920.Research foci:1) Clinical pharmacology and clinical trials of antiepileptic drugs, especially trial design, pharmacokinetics, and side effects.2) Epidemiology of epilepsy in elderly and disadvantaged populations, especially using large databases to explore quality of care.21.Grant Support:a. Current support:“Epidemiology of epilepsy using nationwide databases”, E Faught PI (co-PI 2012-15, PI from 2016), (2012-indefinite) Individual project budgets, UCB Pharma, 2012-17 approx. $81,000/year, 2017-18 $198,000; Faught individual support 15% salary + fringe approx. $99,000 calendar yrs 2018 and 2019“Neuropsychological effects of laser ablation of mesial temporal structures”, Daniel Drane PI, NIH NINDS E Faught consultant, 1% salary support“Phase II trial of a new potassium-channel agent for refractory focal onset seizures”. Faught E PI. Xenon; 2019-2021, funding will vary b. Previous support (Federal support in bold)UAB:Previous Research as Principal Investigator or Site Principal Investigator“Steady-state and transient visual evoked potentials in normal children and adults”, Graduate School Faculty Research Award, University of Alabama in Birmingham, 1982 (Principal investigator) “Random, controlled clinical trial of cyclo-prostin (PGI2) in acute atherothrombotic strokes and embolic strokes of cardiac origin”, Upjohn Co. grant, 1983-1984 (Site PI) “Development of tolerance to caffeine in the maximal electroshock seizure model in rodents,” NIH student summer research training grant, Mark Fletcher, 1985 (Faculty sponsor) “Multicenter controlled study of the use of pentastarch vs. standard medical treatment in the management of acute cerebral infarction”, American Crit. Care, Inc, 1985-1986 (Site PI) “Master agreement for the clinical evaluation of antiepileptic drugs”, NIH-NINDS, approved 1987-1998. (Specific protocols varied.) Approved areas: Dose tolerance and pharmacokinetic studies, tolerance and preliminary efficacy studies, and controlled clinical trials of efficacy and safety (Phases I, II, III, and IV; Children and Adults) (Principal Investigator)“A double-blind placebo-controlled trial of three doses of topiramate or placebo in refractory partial epilepsy”, McNeil Pharmaceuticals, 1988-1990 and “follow-up open-label extension studies,” 1988-1995 (site PI) “A multicenter placebo-controlled, parallel-design, dose-response evaluation of the safety and efficacy of lamotrigine as add-on therapy in outpatients with partial seizures”, Burroughs-Wellcome , 1988-90 (site PI)“Open label extension treatment with lamotrigine - BW 10”, Burroughs-Wellcome Co., 1989-1991 (site PI)“Evaluation of selected computerized EEG frequency analysis parameters in patients with Alzheimer’s Disease”, NIA-NIH, 1987-1990 (Co-Investigator for EEG Core Data, Alzheimer’s Program Project Grant, Lindy Harrell, M.D., Ph.D., Principal investigator) “Open extension protocol for topiramate treatment in refractory partial epilepsy”, McNeil Pharmaceuticals, YKT, 1989-1993 (site PI) “A randomized, placebo controlled efficacy and safety evaluation of losigamone in the treatment of partial seizures,” Dr. Willmar Schwabe GmbH & Co., 1995-1996 (site PI)“Clinical experience/use of Sabril in pts with partial seizures,” Marion Merrell Dow, (site PI)A double-blind, placebo-controlled, phase III study of lamotrigine in complex partial seizures,” Clinical Res.International, 1989-1990 (site PI) “Monotherapy comparison of felbamate and valproate in partial seizures, Carter-Wallace, 1989-1990 ( sitePI) “Treatment of generalized convulsive status epilepticus”, Veterans’ Administration Cooperative Study #265, 1990-1995 (Site PI) “Study of felbamate as monotherapy in subjects undergoing surgical evaluation of partial epilepsy”, Carter-Wallace, Inc., 1990-1991 (site PI) “Remacemide inpatient seizure evaluation trial,” National Institute of Neurological Disorders and Stroke - NIH, NO1-NS-7-2312, MAO#2, 1991-1995 (Site PI) “Felbamate for initial treatment of tonic-clonic seizures,” Carter-Wallace, 1993-1994 (site PI) “Neuropsychological effects of felbamate monotherapy,” Carter-Wallace, Inc., 1993-1994 (PI)“A double-blind, placebo-controlled, parallel, efficacy and safety study of topiramate in patients with partial epilepsy followed by topiramate single therapy as accomplished by the reduction of concomitant Tegretol (carbamazepine)or Dilantin (phenytoin) (two protocols, 1992-1995), R.W. Johnson Pharmaceutical Research Inst. (site PI)“Rectal administration of diazepam in acute repetitive seizures,” National Institute of Neurological Disorders and Stroke - NIH, NO1-NS-7-2312, MAO#1, 1991-1994 (Co-site PI) “Felbamate Concentration-Response Trial,” National Institute of Neurological Disorders and Stroke - NIH, NO1-NS-7-2312, MAO #3, 1991 - 1995 (Site PI) “A double-blind, randomized, placebo-controlled, parallel group dose response study of vigabatrin in patients with uncontrolled complex partial seizures,” Merrell Dow Research Institute, 1991-1993 (site PI) “The safety of intravenous Depakote,” Abbott Laboratories, 1991-1992 (Principal Investigator) “An open-label study of felbamate in refractory epilepsy,” Wallace Labs, 1989-1994 (site PI)“One year maintenance study of vigabatrin following completion of a double-blind dose response study,” Merrell Dow Research Institute, 1991-1993 (site PI) “An open study of Lamictal in epileptic outpatients,” Burroughs-Welcome, 1990-1994 (site PI)“A multicenter, open-label, long-term evaluation of the safety of felbamate in children with epilepsy,” Wallace Laboratories, 1994-1995 (site PI) “Multicenter topiramate monotherapy trial,” R.W. Johnson Pharm. Res.Inst/, 1993-94(site PI)“Randomized trial of tirilizad in acute stroke,” Upjohn Co., 1993-1995 (site PI) “Placebo controlled efficacy and safety evaluation of zonisamide in the treatment of seizures in medically refractory patients,” Dainippon, 1994-1995. (site PI) “Double blind study of the safety and efficacy of intermittent rectal administration of diazepam for acute repetitive seizures,” Athena Neurosciences, 1995 (site PI)“Multicenter, double-blind, randomized, stratified, placebo-controlled, two-arm parallel trial of oxcarbazepine in inpatients undergoing evaluation for epilepsy surgery,” Ciba-Geigy, (site PI) “Phase I and II trials of SKB204269 for partial onset seizures. Smith Kline, (PI) (1996 - 1998)“A double-blind, placebo-controlled, study to evaluate the safety, tolerability, and antiepileptic activity of ganaxolone in patients undergoing evaluation to determine suitability for surgical treatment of CPS,” CoCensys Inc, (site PI) (1996 - 2000)“A long-term follow-on open study of remacemide hydrochloride for safety and tolerability in patients with medically refractory epilepsy,” Fisons Corporation, (site PI) (1996 - 2000)“Losigamone as monotherapy in the treatment of complex partial seizures”, NINDS, National Institutes of Health (Site PI) (1997-1999)“Open-label extension trial of oxcarbazepine in partial seizures,” Ciba-Geigy, (site PI)“Long-term safety and efficacy evaluation of zonisamide in the treatment of seizures in medically refractory patients and efficacy evaluation of zonisamide monotherapy. Extension of treatment”, Dainippon Pharmaceutical Co. Ltd. (site PI) (1994-2000)“Open-label dose titration assessment of the use of a low dose titration schedule of zonisamide in the initiation of therapy with partial seizures”, Elan Pharmaceuticals (site PI) (1999-2000)“Topiramate monotherapy clinical trial in subjects with recently diagnosed partial-onset seizures”, R.W. Johnson Pharmaceutical Research Institute (site PI) (2000-2001)“Electrical stimulation to terminate after-discharge potentials”, NeuroPace, Inc (PI) (2000-2002)“Treatment of Seizures in Elderly Adults: VA Cooperative Study 428”, Department of Veterans’ Affairs Research Service (Site PI (1997-2003).“Pregabalin open-label add-on trial: an open-label, multicenter follow-on study to determine long-term safety and efficacy in partial seizures”, Parke-Davis (site PI) (1998-2003)“Rapid infusion of valproate: pharmacokinetics and tolerability”, Abbott Laboratories (Co- Principal Investigator with N. Limdi) (2001-2002)“Harkoseride Phase II Clinical Trial”, Schwarz Pharma (site PI) (2001-2003)“Lamotrigine in Patients with Epilepsy and Depression”, GlaxoSmithKline (site PI) (2002-2004)“Comparison of Phenytoin and Topiramate Oral Loading for Initial Therapy of Partial-onset Seizures” Ortho- McNeil (CAPSS trial) (site PI) (2006-2008)“E2007 (perampanel) Phase II and III Clinical Trials” Eisai (site PI) (2004-2009)“Lacosamide Phase III Clinical Trials” Schwarz Pharma (Site PI)“RWJ 333369 (carisbamate) Phase III Clinical Trial” Ortho-McNeil (PI) (2006-2008)“Retigabine Phase III Clinical Trial” Valeant (Site PI) (2006-2009)“Ganaxolone Phase II Clinical Trial” Marinus (Site PI) (2007-2009) “Pregabalin Monotherapy Trial”, Pfizer (Site PI) (2007-2009)EMORY; “Economic and medical effecs of vagus nerve stimulation on the Medicaid population”, PI, The Analysis Group and Cyberonics, Inc.. (2011-2012, $32,000). Impact of uncontrolled epilepsy on Medicaid and privately insured populations .PI. The Analysis Group and GlaxoSmithKline (2010-2012, $8000)Brain Sentinel, “Clinical trial of seizure warning system”, E Faught site PI, 2013-2016,($82,500)“Briviact Phase IV persistence and tolerability trial UCB Pharma (2018-2019)Previous Research as Co-Investigator:UAB:“Topiramate monotherapy clinical trial in subjects with recently diagnosed partial-onset seizures”, R.W. Johnson Pharmaceutical Research Institute, 1994-1995 (F. Gilliam, site PI) (1995-1996)“Homocysteine and vitamin levels in patients treated with lamotrigine, valproate, phenytoin, or carbamazepine monotherapy”, UAB Faculty Research Initiatives Program, (T. Tamura, PI) (1995-1997)“Safety and efficacy of Depakote monotherapy in complex partial seizures”, Abbott Laboratories, (R. Kuzniecky, site PI)(1990-1994)“Safety and efficacy of tiagabine HCL monotherapy for the treatment of partial seizures: high doses vs. low doses”, Abbott Laboratories, (R. Kuzniecky, site PI) (1994-1995)“Safety and efficacy of high vs. low-dose oxcarbazepine monotherapy for patients with uncontrolled partial-onset seizures”, Ciba-Geigy, (R. Kuzniecky, site PI) (1995-1996)“Vigabatrin monotherapy trial for partial-onset seizures”, Hoechst Marion Roussell, (R. Kuzniecky, site PI) (1995-1997)“Efficacy/safety of lamotrigine monotherapy,” GlaxoWellcome, 1994-96 (F. Gilliam, site PI).“LTG treatment of partial seizures in pediatric. patients”, Glaxo Wellcome, (M. Wise, site PI)“Oxcarbazepine tablets - pediatric trial”, Ciba-Geigy, (M. Bebin, site PI) (1995-1997)“Safety of oral adjunctive vigabatrin ”, Marion Merrell Dow, (M. Bebin, site PI) (1995-96)“Long term maintenance therapy with vigabatrin as adjunctive therapy in childhood partial seizures”, Marion Merrell Dow, (M. Bebin, site PI) (1995)“Gabapentin pediatric monotherapy trial”, Parke-Davis, (M. Bebin, site PI) (1994-1996)“Lamotrigine and carbamazepine cognitive effects in healthy elderly subjects”, Glaxo Wellcome, (R. Martin, PI) (1999-2000)“Rufinamide presurgical trial”, Novartis. (J. McBurney, site PI) (1999-2001)“Levetiracetam monotherapy trial for partial-onset seizures. (R. Knowlton, site PI) (2000-2001)“Prenatal effects of AEDs- NEAD trial”, NIH-NINDS, (K. Meador, PI) (2001-2006)“Zonisamide - phenytoin interactions”, Elan, (T. Welty, PI) (2001-2002)“Talampanel clinical trials” Eisai (A. Prasad and R. Knowlton, site PI) (2001-2006) “Implantable responsive neurostimulator for epilepsy” Neuropace (L. Paige, site PI) 2006-8 “Lacosamide monotherapy trial” Pfizer (J. DeWolfe, site PI) 2007-2009 “Clobazam for refractory pediatric epilepsy” Lundbeck (M. Bebin, site PI) 2007-2009“Epilepsy Phenome-Genome Project”,NIH-NINDS (R. Knowlton, UAB site PI) (2007-2010)EMORY:“Incidence and clinical effects of epilepsy in elderly individuals”, CDC/AAMC Co- investigator (PI; Maria Pisu, Ph.D.) (2008-2012) UAB subcontract to Emory 2010-12)The Epilepsy Consortum. Funding from NIH/Epilepsy Foundation/CURE. “Human Epilepsy Project”, E Faught Pharmacology Core Member, PIs Daniel Lowenstein, Ruben Kuzniecky, Jacqueline French 2013-2020.NIH 1 RO1 NS080898-01 “QUIET CARE (Quality of epilepsy treatment and costs in older Americans by race)”, Maria Pisu, PI, Univ. of Alabama at Birmingham, E Faught, Consultant, $5000/yr, 2013-2017“Cenobamate Phase 2 Trial for Refractory Epilepsy”, K Bullinger Site PI, E Faught co PI, SK Life Science, 2018-2019, funding varied22.Clinical Service Contributions:2019-2020 academic year (inpatient total- 18 weeks)Emory University Hospital Epilepsy Monitoring Unit attending- 6 wksEUH Intracranial EEG Monitoring Service attending- 4 weeksEUH/EUHM/ESJH ICU EEG service attending- 4 weeksGrady Memorial Hospital Epilepsy/EEG Service- 8 weeksThe Emory Clinic Epilepsy Clinics/EEG Education Service- 5 weeks (5 teaching clinics/week + outpatient EEG reading with residents and fellows 5 half-days/week)Grady Memorial Hospital Intraoperative Monitoring- 1 weekend every 5 weeksEpilepsy Outpatient Cinics- 3 half days/week when not on services 1-5 aboveIntraoperative Monitoring Service- EUH/ESJH/EUHM/EUOSH 1 day/week2010-2018. Emory Healthcare- similar to 2018-19.Previous Clinical Service- AcademicUAB:1978-79Chief, Neurology Service, Salem VA Hospital Salem, VA- 12 mos: consults, EEGs, EMGs1980-2009Attending Physician, Neurology Inpatient or Consult Services, University of Alabama Hospital, average 6 months/year 1980-1995, 1.5 months/ year 1996-2007Attending Physician, Birmingham Dept. of Veterans Affairs Med. Ctr. Neurology Service, average 2 months/year, 1980-2009Attending Physician, Penfield Epilepsy Service, University of Alabama Hospital, average 4 months/year 1990-2009Attending Physician, Vascular/Crit.Care Neurol/ Svc, Univ. of AL Hosp, 1 month/yr 2006-8UAB Adult Epilepsy Clinic and satellite clinics, average 2.5 half-days/week 1981-2009Children’s Rehabilitation Service of Alabama Pediatric Ep. Clinics, biweekly, 1982-199423. Formal Teaching:a. Medical Student/Resident Teaching University of Alabama School of Medicine, approximately 2 lectures/year to full 1st or 2ndyear class, pharmacology or neuroscience courses,1985-2007 Attending Physician on UAB teaching services as above, medical student rotations on neurology service required from1998-2009 Attending Physician, EUHM neurology clerkship, Emory SOM 2010 -20 Att. Physician, Emory Epilepsy Monitoring Unit and ICU EEG services, 2010-2020 Att. Physician, Emory Intracranial Monitoring service, 2016-19 Att. Physician, The Emory Clinic Epilepsy Education Service, 2016-2019 5 lectures/yr to Emory neurology residents or clinical neurophysiology/ epilepsy fellowsb. Graduate Programs Doctoral Dissertation Committees Bryan Connell, Ph.D., Neurosychology, 1991 Shawn Bachtler, Ph.D., Neuropsychology, 1994 Mentor, NIH Clinical Investigator Development Awards Frank Gilliam MD, MPH. 1995-2000. “Outcomes of Epilepsy Surgery” (K23) (currently Professor, University of Kentucky, formerly Director, Epilepsy Centers, Washington University and Columbia University) Nita Limdi PharmD, MPH,. PhD. 2003-2008. “Drug Metabolism and Genotype” (K23) (currently Professor of Neurology and Genetics, University of Alabama at Birmingham Residency ProgramsDirector, Neurology Residency Program, Univ. of Alabama Med. Center, 1983-1990Assoc. Director, Clinical Neurophysiology Res. Program, Univ. of AL Medical Ctr, 1996-2009Resident and Fellow rotations on Epilepsy Monitoring Unit, and ICU EEG Service, Emory University Hospital and Grady Memorial Hospital 2010-current Postdoctoral Fellows (As Program or Division Director)Epilepsy and Electroencephalography (From 2000: Clinical Neurophysiology Residency) Fellows at UAB1984-1985Mark Fortson, M.D., Atlanta, GA1984-1985Elliott Hurwitz, M.D., Salem, MA1985-1986Asish Ghoshal, M.D., Sacramento, CA1988-1989Subroto Kundu, M.D., Walnut Valley, CA1989-1990Michael Hevor, M.D., Los Angeles, CA1990-1992Zeava K. Rubin, M.D., Director, Clinical Neurophysiology, SocialSecurity Hospital, University of Panama1992-1993Emilio Gatti, M.D. (Clinical Neurophysiology), Detroit, MI1992-1993Gregory Wheatley, M.D. (Epilepsy), Knoxville, TN1993-1994Diane Donley, M.D., Traverse City, MI1994-1995William J. Craven, M.D., Ph.D., Charlotte,North Carolina1994-1996Erhan Bilir, M.D., Neurology Faculty, Ankara University, Ankara, Turkey1995-1997Eva Laich M. D. Neurology Faculty, Wagner-Jauregg NeurologischeKlinik, Linz, Austria1996-1998Adil Khan, M.D., Indianapolis, IN1998-2000Timothy Powell, M.D., Director, Rockford Clinic Epilepsy Center, Spokane, WA1999-2000Nicholas Lawn, M.D., (Epilepsy), Professor,Univ. Western Aust., Perth, Australia2000-2001Diane Counce, M.D., Birmingham, AL2000-2001Prasad Kanneganti, M.D., Springfield, MOJorge Burneo, M.D., Professor,, University of Western Ontario, London, CanadaDalia Miller, M.D., Springfield, MO2003-2004Lawrence Ver Hoef, M.D., Assoc Professor,UAB Neurology, Birmingham, AL2004-2005Mary Taylor, M.D., Morehouse Neurology Clinical Faculty,Atlanta, GA2005-2006Jennifer DeWolfe, D.O., Assoc Professor, UAB Neurology, Birmingham, ALDinu Nodit, M.D., Knoxville, TN2006-2007Amit Arora, M.D., Assoc Professor, UAB Neurology Faculty, Huntsville, AL2007-2008Ro Elgavish, M.D., Denver, CO2008-2009Neil Billeaud, M.D., Ochsner Clinic Neurology Faculty, New Orleans, LA2008-2009Thomas Gann, M.D., Charlotte, NC2009-2010 Evan Gedzelman, M.D. Asst Professor, Emory Univ Neurology, Atlanta, GA Fellows at Emory during service as Epilepsy Program Director2013- currentFour fellows/year, Epilepsy/EEG track, Clinical Neurophysiology residency2016-currentTwo fellows/year, Epilepsy; three fellows/year Clinical Neurophysiology Epilepsy/EEG track residency, 1 fellow/yr combined EEG/EMG trackd. Other TeachingEmory undergraduate course “Clinical Neurology”, Mentor, 2013, 2014NIH/UAB Summer Research Fellowship, Mark Fletcher (medical student), 1984UAB Epilepsy Center Summer Research grant, Michael Lyerly, medical student, 2005 (now Associate Professor of Neurology, UAB)Emory Epilepsy Course “New Drugs for Epilepsy”, yearly, 2011-2014, 201724.Lectureships, Seminar Invitations, and Visiting Professorships: Lecture, “Seizures in Older Persons”, Alabama Neurological Society, Aug 24, 2019 Visiting Professor, University of Nebraska, Dept. of Neurology, May 23-26, 2017. Neuroscience Grand Rounds, “Surgery for Epilepsy”, Ochsner Medical Foundation, New Orleans, LA, March 2015Lecture/Debate, “Rational Polytherapy: Not Yet”, Dec 4, 2008, American Epilepsy Society Annual Course, Seattle.Hans Berger Lectureship Award, “An Approach to Refractory Epilepsy”, Medical College of Virginia/monwealth University 2005Invited lectures, Turkish Neurological Society and “Epilepsy Days” Izmir, Turkey 2004Visiting Professor, Netherlands Neurological Association, November 26-30, 2000Lectures at: University of Maastricht (Neurology Grand Rounds), Epilepsy Center “Meer im Bosch” (Heemstede), University of RotterdamSaudi Arabian Epilepsy Society, lectures in Riyadh and Jeddah, and Neurology Rounds at King Faisal Specialty Hospital, September 10-12, 2000Lecture, “New Antiepileptic Drugs”, AAN course, “Clinical Epilepsy”, May 4, 2000Lecture, “New Antiepileptic Drugs”, AAN course, “Clinical Epilepsy”, April 30, 1999Lecture, “Choice of Drug by Mechanism. of Action and Efficacy”, AAN. course, “Clinical Epilepsy”, April 26, 1998 Lecture, “New Antiepileptic Drugs”, AAN course, “Neuropharmacology”, 4/27/98Visiting Professor, Univ. of Virginia, Dept. of Neurology., Charlottesville, May 22-23, 1997Visiting Professor, Univ. of Mississippi, Dept. of Neurology, Jackson, January 18-20, 1996Visiting Professor, Univ. of Michigan, Dept. of Neurology, Ann Arbor, January 24-27, 1994Lecture, “Treatment of the Generalized Epilepsies,” Am. AAN course, April 29, 1994Visiting Professor, Medical Coll. of Georgia, Dept. of Neurology, Augusta, May 11-12, 1993Visiting Professor, University of Cincinnati, Dept. of Neurology, Nov 12-13, 1993Visiting Professor, Univ. of Kentucky, Dept. of Neurology, Lexington, Oct 14-16, 1992Presidential Lecture, “The Future of EEG”, Southern EEG Soc., Asheville, NC, Mar 15, 199025.Invitations to National or International Conferences (Lectures/Presentations): 2019 Epilepsy Society of Australia, Sydney, Invited speaker, “Epilepsy in the Elderly” International Epilepsy Congress, Bangkok, Thailand, invited speaker, “Treatment Gaps in Epilepsy I: Diagnosis to Treatment”.2018 and 2019 EEG in Epilepsy, Mechanisms of Action of AEDs, Presurgical Evaluation, Surgery for Epilepsy, Autoimmune Epilepsies, Status Epilepticus,Reflex Epilepsy. (Lectures). Penry Residents’ Programs and Penry Fellows’ Programs, 2 programs per year, Wake Forest University, Winston-Salem, NC 2017. Epilepsy: Levels of Care (Lecture) American Society of Managed Care Professionals, Las Vegas, NV, Oct 27, 2017. EEG in Epilepsy, Mechanisms of Action of AEDs, Presurgical Evaluation, Surgery for Epilepsy, Reflex Epilepsy. (Lectures). Penry Residents’ Program, June 2017, Wake Forest University, Winston-Salem, NC Epilepsy in Older Persons, and Career Trajectories in Academic Neurology (Lectures) May 2017, University of Nebraska, Omaha 2016. Characterization of antiepilepsy drug use in older people. Asian-Oceanian Epilepsy Congress, Hong Kong (platform presentation) Healthcare utilization during the first year after epilepsy diagnosis. Am Acad. Of Neurology, Boston (platform presentation) History and Epidemiology, EEG in Epilepsy, Mechanisms of Action of AEDs, Presurgical Evaluation, Surgery for Epilepsy, AED Side Effects. (Lectures). Penry Residents’ Program, Wake Forest University, Winston-Salem, NC 2015. EEG in Epilepsy, Mechanisms of Action of AEDs, Presurgical Evaluation, Surgery for Epilepsy, Reflex Epilepsy. (Lectures). Penry Residents’ Program, Wake Forest University, Winston-Salem, NC 2014. EEG in Epilepsy, Neuroimaging, Surgical Selection and Techniques, Reflex Epilepsies (Lectures), Penry Epilepsy Fellow’s program, Wake Forest University, Winston-Salem, NC (two programs during 2014) 2013 Mechanisms of Action of AEDs, EEG in Epilepsy, Diagnostic Tests in Epilepsy, Selection of Patients for Surgery, Surgery for Epilepsy: Techniques and Outcomes New Drugs for Epilepsy (Lectures).Penry Epilepsy Resident’s Program, Wake Forest University, Winston-Salem, NC; and Penry Fellow’s programs (20. 2012 Clinical Trials: The View from the Clinic. International Symposium on The Future of Clinical Trials, Univ. of Lyon, Lyon, France (invited speaker) 2011 Women with Epilepsy, Managing Antiepileptic Drug Interactions, Mechanisms of Action of AEDs, Lacosamide and Retigabine, Reflex Epilepsies, Normal EEG Variants (Lectures) Advances in Epilepsy Course (for neurologists in practice), Wake Forest Univ., Winston-Salem NC (Cat. I CME)2010 Three New Drugs, Southern Epilepsy and EEG Society, Asheville, NCAdverse Effects of Antiepileptic Drugs, Antiepileptic Drug Interactions, New Drugs, and Status Epilepticus, Penry Epilepsy Program for Residents, Wake Forest Univ., Winston-Salem, NCNeurology Grnd.Rnds, “Nonadherence to AEDs: Morbidity and Mortality”, UAB2009 Carisbamate Pharmacokinetic Studies. .Intl. Epilepsy Congress, Budapest, Hungary.Nonadherence to Antiepileptic Drugs: Mortality and Morbidity. Emory Univ. Neurol. Grand Rounds, Atlanta, GAMechanisms of Action of AEDs, EEG in Epilepsy, Diagnostic Tests in Epilepsy,Selection of Patients for Surgery (Lectures).Penry Epilepsy Resident’s Program, Wake Forest University, Winston-Salem, NCProfessor’s Rounds, Univ. of South Alabama Dept of Neurology, Mobile, AL2008 The Importance of Monotherapy. Emerging Nations Neurology Conference, SingaporePsychological Side Effects of AEDs.Neurology. Grand Rounds. Med. Coll. of Georgia, AugustaHistory of Epilepsy, Mechanisms of Action of AEDs, Classification of Sz, Class.of Epilepsies. Penry Epilepsy Minifellowship, Wake Forest Univ., Winston-Salem NC.2007 Update on the New Drugs. National Epifellows Foundation (Am. Epilepsy Soc. Satellite meeting), Philadelphia, PA.Antiepileptic Drug Side Effects. Neurol. Grand Rounds, Wake Forest Univ., Winston-Salem NCMood and Behavioral Effects of AEDs. Neurology. Grand. Rnds, Medical College of Virginia. (VCU), Richmond,VAFelbamate in Refractory Epilepsy. Seminar, Pediatric Neurology Division, University of Mississippi, JacksonEEG in Epilepsy, Special Techniques, MRI in Epilepsy (Lectures).Penry Epilepsy Program for Residents, Wake Forest Univ., Winston-Salem, NC Refractory Epilepsy.Neurology Grand Rounds.Univ.of Louisville, Louisville, KY. Antiepileptic Drugs. Neurol. Grand Rounds, Univ. of KY, Lexington, KY, Antiepileptic Drugs2006Partial-onset Seizures. Neurology Grand Rounds. LSU, New Orleans, LAReview of felbamate side effects. Seminar, American Epilepsy Society, San Diego, CADifficult-to-treat Epilepsies. Neurology Grand Rounds, Univ. of Tenn., Memphis, TNAdverse Effects of Antiepileptic Drugs. Neurol. Grand Rounds, Univ of MS, Jackson, Felbamate. Eilat VIII Conference on New Antiepileptic Drugs, Sitges, SpainChoice of Drug for Epilepsy. Staff conf., Case Western Reserve Univ., Cleveland, OHApproach to the Refractory Patient.Hans Berger Lecture. MCV/VCU, Richmond, VASeizure Monitoring Cases. Lecture for the Hans Berger Symposium, MCV/VCU, Richmond, VARefractory Generalized Epilepsy. Neurol. Grand Rounds, Univ. of Virginia, Charlottesville, VASequential Treatment of Epilepsy. Neurol. Grand Rounds, Syracuse Univ., Syracuse, NYPartial-onset Seizures. Neurology seminar, Univ. of Rochester, Rochester, NY2005 New Antiepileptic Drugs. Epilepsy seminar, Duke University, Durham NC, An Approach to Refractory Seizures, Neurol. Grand Rnds., Vanderbilt Univ., Nashville, TNRefractory Epilepsy. Univ of Washington Neurology Grand Rounds, Seattle, WAAdverse Effects of Antiepilepsy Drugs, Harborview Hospital, Seattle, WANew-onset Seizures, Neurology Seminar, Indiana University Hosp., IndianapolisAdverse Effects of Antiepilepsy Drugs, Neurology Grand Rounds, LSU, Shreveport, LA Behavioral and Cognitive Effects of AEDs. Neurol.Grnd.Rnds, MCG, Augusta, GA Neuroimaging in Epilepsy, New-onset Seizures, Status Epilepticus, Epilepsy Surgery, and EEG in Epilepsy. Lectures, The J.Kiffin Penry Minifellowship, Wake Forest Univ., Winston-Salem, NCInvited Lectures Before 2005 - Upon Request26.Other Activities: Directorships of Continuing Education Courses2/24/84“EEG Technology” ABRET Board Review Course, UAB, Birmingham, AL8/2/85“Understanding Epilepsy” for health care professionals, UAB, Birmingham, AL4/11/86“New Concepts in Epilepsy, 1986” for physicians, UAB and Alabama Council on Epilepsy, Birmingham, AL 5/9-5/11/88“Advances in Epilepsy” for physicians, UAB and Alabama Council on Epilepsy, Lake Guntersville State Park, Alabama1/12/89“New Techniques in Clinical Neurophysiology”, Symposium, Southern EEG Society, St. Petersburg, Florida1/13/89Moderator and Program Chairman, Scientific Session, Southern EEG Society, St.?Petersburg, Florida10/14/92“Practical Management of Seizure Disorders”, for physicians, CoChairman, University of Mississippi/UAB/EFA sponsorship, Pass Christian, MS12/3/93“International Epilepsy Conference”, for physicians and other health professionals, Co-Course Director, UAB, Birmingham, AL3/5/94“Review of Clinical Neurophysiology”, Southern EEG Society Annual Course, Atlanta, GA7/16-17/94“Practical Neurology”, Med. Assoc.State of Al. course, Co-Course Director, Gulf Shores, AL3/15/95“Clinical Neurophysiology in Epilepsy”, South. EEG Soc. Annual Course, San Antonio, TX4/19-20/96Moderator and Program Chairman, Scientific Session, Southern EEG Society, Orlando, FL4/30/97“EEG in Status Epilepticus”, Breakfast Seminar, American Academy of Neurology annual meeting, Boston, MA5/9-10/97“A Neurology Course for Primary Care Physicians”. Director, UAB, Bham., AL5/1/98“EEG in Status Epilepticus”, Breakfast Seminar, American Academy of Neurology annual meeting, Minneapolis, MN12/4/00“Antiepileptic Therapy Symposium: Matching the Medicine to the Patient”, Director, American Epilepsy Society annual meeting, Los Angeles, CA2/10/01“New Antiepileptic Drugs: A Course for Psychiatrists”, Director. UAB, Birmingham, AL12/5/01“Antiepileptic Therapy Symposium: Special Topics in Status Epilepticus,” Director, American Epilepsy Society annual meeting, Philadelphia, PA12/4/02“Antiepileptic Therapy Symposium: The Challenge of Adverse Events”, Director, American Epilepsy Society annual meeting, Seattle, WA4/28/07“Managing Seizures in Long-Term Care”, Director. UAB and the Southern Epilepsy and EEG Society, Birmingham, AL6/21/13‘Rational Polytherapy in Epilepsy”, Symposium Director, International Epilepsy Conference, Montreal, Canada8/24/2019. “Epilepsy in Older Adults”, Alabama Neurological Society, Birmingham26. Other Activities- Miscellaneous Training Research Award, American Heart Association, Middlesex Hospital Medical School, University of London, Jun-Aug 1971 Neurology clinical clerkship, Yale University, Oct-Nov 1971 Officer Advanced Course, US Army, San Antonio, TX, 1991, 2 weeks Command Course, US Army, Indianapolis, IN. October 1996 Leadership Course for Department Chairs and Chiefs of Clinical Services, Harvard School of Public Health (in residence) Boston, MA, 2 wks, 1999. Advanced Leadership Course, 1 week, 2001.27.Bibliography (Peer reviewed-240; Total-308) Web of Science: #F2267-2010, publication list 371, 12,390 citations, H-factor 61Accessed March 1, 2020 Published and accepted research articles in refereed journals:1.Faught E, Trader S, Hanna G. Cerebral complications of angiography for transient ischemia and stroke: prediction of risk. Neurology 29:4-15, 19792.Slevin J, Faught E, Hanna G, Lee SI. EEG abnormalities in migraine: epiphenomena of headache or medication? Headache 24:251-254, Nov., 19813.Faught E, Falgout J, Leli D. Late-onset variant of Huntington’s chorea.Southern Medical Journal 76:1266-1270, Oct., 19834.Faught E, Lee SI. Pattern-reversal visual evoked potentials in photosensitive epilepsy. Electroenceph Clin Neurophysiol 59:125-133, 19845.Faught E, Oh SJ. Brainstem auditory evoked responses in brainstem infarction. Stroke16(4):701-705, 19856.Faught E, Falgout J, Nidiffer F, Dreifuss F. Self-induced photosensitive absence seizures with ictal pleasure. Archives of Neurology 43:408-410, 19867.Yatsu F, Linet O, Hsu CY, Faught E, Furlan A, Coull B, Hogan E, Huang D. Controlled clinical trial of epoprostenol in acute stroke.Proceedings of the 1985 Sienna Stroke Symposium. New York, Raven, 19868.Yatsu F, Grotta J, Pettigrew L, Gray J, Hogan E, Hsu CY, Faught E, Furlan A, Coull B, Linet O, Huang D, Kent I. Prostacyclin infusion for acute ischemic strokes.Proceedings of the 3rd International Neurological Symposium. London: Transmedica, 19869.Faught RE, Chandra-Sekar B, Bonnin J, Crossley G. A 34-year-old man with recent onset of ataxia.Ala J Med Sci 23:408-413, 198610.Hsu CY, Faught RE Jr, Furlan AJ, Coull BM, Huang DC, Hogan EL, Linet OI, Yatsu FM. Intravenous prostacyclin in acute nonhemorrhagic stroke: a placebo-controlled double-blind trial. Stroke 18:352-358, 198711.Faught E. Methaqualone withdrawal syndrome with photo-paroxysmal response and high-amplitude visual evoked potentials. Neurology 36:1127-1129, 198612.Garcia JH (ed ), Heinsohn ME, Gupta KL, Faught RE, Bonnin JM. Encephalopathy in a 68-year-old man. South Med J 80(10):1277-1284, 198713.Faught E, Lee SI. Pattern-reversal visual evoked potentials in photosensitive epilepsy. Electroenceph Clin Neurophysiol 59:125-133, 1984 14.Gupta K, Duvall E, Vitek J, Stanley R, Faught E. Occult gliomas demonstrated by serial CT scans in new onset of seizures. Ala J Med Sci 25(2):159-163, 198815.Faught E, Peters D, Bartolucci A, Moore L, Miller PC: Seizures after primary intracerebral hemorrhage. Neurology 39:1089-1093, 198916.Duke L, Harrell LE, Callaway R, Jope R, Gu X, Faught E, Kuechenmister C, Kuechenmister S and Linton P. Further characterization of physostigmine responders and nonresponders in Alzheimer’s Disease by physiological and biochemical methods. Neurology 40(Suppl 1):228, 199017.Kuzniecky RI, Faught E, Morawetz R. Surgical treatment of epilepsy: Initial results based upon epidural electroencephalographic recordings. South Med J 83:637-639, 199018.Kuzniecky R, Faught E. Epidural electrodes in partial epilepsy.Neurology 40:1009-10, 199019.Kuzniecky RI, Garcia JH, Faught E, Morawetz, R. Cortical dysplasia in temporal lobe epilepsy: magnetic resonance imaging correlations. Ann Neurol 29:293-298, 199120.Kuzniecky RI, Faught E. , Morawetz R. Electroencephalographic correlations of extracranial and epidural electrodes in temporal lobe epilepsy.Epilepsia 32:335-340, 199121.Kuzniecky R, Suggs S, Gaudier J, Faught E. Lateralization of epileptic foci by magnetic resonance imaging in temporal lobe epilepsy.J Neuroimaging 1(4):163-167, 199122.Kuzniecky R, Rubin Z, Faught E, Morawetz R: Anticonvulsant treatment following temporal lobectomy: Carbamazepine vs. polytherapy. Epilepsia 33(5): 908-912, 199223.Faught E, Kuzniecky R, Hurst DC: Ictal EEG waveforms from epidural electrodes predictive of seizure control after temporal lobectomy. EEG and Clin. Neurophysiology 83:229-235, 199224.Kuzniecky R, Murro A, King D, Faught E, et al: MRI in childhood intractable partial epilepsies: pathological correlations. Neurology 43:681-687, 199325.Faught E, Sachdeo R, Remler M, I-Madoz V, Ramsay R, Sutula T, Kanner A, Kuzniecky R et al: Felbamate monotherapy for partial onset seizures: an active-control trial. Neurology 43:688-692, 199326.Cascino G, Andermann F, Berkovic S, Kuzniecky R, Faught E, et al: Gelastic seizures and hypothalamic hamartomas: Evaluation with chronic EEG monitoring and outcome of surgical treatment. Neurology 43:747-751, 199327.Kuzniecky R, Burgard S, Faught E, et al: Predictive value of MRI in temporal lobe epilepsy surgery. Arch. Neurol 50(1):65-69, 199328.Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, Lineberry CG for the U.S. Lamotrigine Protocol 05 Clinical Trial Group. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures.Neurology 43:2284-2291, 199329.Kuzniecky R, Andermann F, Guerrini R, and the CBPS Multicenter Collaborative Study: E Faught et al. Congenital bilateral perisylvian syndrome: study of 31 patients. Lancet 341:608-612, 199330.Kuzniecky R, Murro A, King D, Morawetz R, Smith J, Powers R, Yaghmai F, Faught E, Gallagher B, Snead OC. Magnetic resonance imaging in childhood intractable partial epilepsies. Pathologic correlations. Neurology 43:681-687, 199331.Kuzniecky R, Andermann F, Guerrini R, and the CBPS Multicenter Collaborative Study: E Faught et al. The epileptic spectrum in the congenital bilateral perisylvian syndrome.Neurology 44:379-385, 199432.Kuzniecky R, Andermann F, and the CBPS Multicenter Collaborative Study Group: E Faught et al. The congenital bilateral perisylvian syndrome: imaging findings in a multicenter study. Am J Neuroradiol 15:139-144, 199433.Roth DL, Goode KT, Williams KL, Faught E. Physical exercise, stressful life experience, and depression in adults with epilepsy.Epilepsia 35:1248-1255, 199434.Nepomuceno C, Hamilton S, Kelly PA, Dasher C, Dietzen CJ, DeVivo MJ, Faught RE. The triad of left hemiplegia, hemihypesthesia, and homonymous hemianopsia: implications for rehabilitation. South Med J 87:905-908, 199435.Williams KL, Roth DL, Kuzniecky R, Faught E, Morawetz R. Psychosocial outcome following temporal lobe surgery.Journal of Epilepsy 7:144-151, 199436.Ben-Menachem E, Manon-Espaillat R, Ristanovic R and Members of the 1st International Vagus Nerve Stimulation Study Group: Faught E et al. Vagus nerve stimulation for treatment of partial seizures: 1. A controlled clinical trial.Epilepsia 35:616-626, 1994 37.Ramsay RE, Uthman BM, Augustinsson LE and Members of the First International Vagus Nerve Stimulation Study Group: Faught E et al. Vagus nerve stimulation for treatment of partial seizures: 2. Safety, side effects, and tolerability.Epilepsia 35:627-636, 199438.George R, Salinsky M, Kuzniecky R and Members of the First International Vagus Nerve Stimulation Study Group: Faught E et al. Vagus nerve stimulation for treatment of partial seizures: Long-term follow-up on first 67 patients exiting a controlled study. Epilepsia 35:637-643, 199439.Adusumalli VE, Wichmann JK, Kucharczyk N, Kamin M, Sofia RD, French J, Sperling M, Dourgeois B, Devinsky O, Dreifuss FE, Kuzniecky RI, Faught E, Rosenfeld, W. Drug concentrations in human brain tissue samples from epileptic patients treated with felbamate. Drug Metab and Disp 22:168-170, 199440.Hetherington H, Kuzniecky R, Pan J, Mason G, Morawetz R, Harris C, Faught E, Vaughan T, Pohost G. Proton nuclear magnetic resonance spectroscopic imaging of human temporal lobe epilepsy at 4.1 T.Ann Neurol 38:396-404, 199541.Devinsky O, Leppik I, Willmore LJ, Pellock JM, Dean C, Gates J, Ramsay RE and the Intravenous Valproate Study Team: Faught E et al. The safety of intravenous valproate.Ann Neurol 38:670-674, 199542.Kuzniecky R, Gilliam F, Faught E. Discordant occurrence of cerebral unilateral heterotopia and epilepsy in monozygotic twins.Epilepsia 36:1155-1157, 199543.Kuzniecky R, Morawetz R, Faught E, Black L. Frontal and central lobe cortical dysplasia: clinical, EEG, and MRI features. Dev Med Child Neurol 37:155-162, 199544.Shachter SC, Leppik IE, Matsuo F, Messenheimer JA, Faught E, Moore EL, Risner ME. Lamotrigine: a 6-month, placebo-controlled safety and tolerance study. J Epilepsy:8:201-209, 199545.Devinsky O, FaughtRE, Wilder BJ, Kanner AM, Kamin M, Kramer LD, Rosenberg A. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res: 20(3):241-246, 1995 Mar46.Bilir E, Faught E, Kundu S, et al. Morbidity of epidural electrode implantation in evaluation for epilepsy surgery.Journal of Epilepsy 9(1):1-4, 199647.Kuzniecky R, Burgard S, Bilir E, Morawetz R, Gilliam F, Faught E, Black L, Palmer C. Qualitative MRI segmentation in mesial temporal sclerosis: clinical correlations. Epilepsia 37(5):433-439, 199648..Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, Karim RM, Kuzniecky R, and the Topiramate YD Study Group. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 46:1684-1690, 199649.Hugg J, Kuzniecky R, Gilliam F, Morawetz R, Faught E, Hetherington H. Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H MRSI.Annals of Neurology 40: 236-239, 199650.Bilir E, Kuzniecky R, Gilliam F, Faught E, Morawetz R, Black L. Temporal Lob Epilepsisinde Mezial Temporal Sklerozun MR ile Segmentasyon Analizi.Epilepsie (Turkey) 2(3):134-138, 199651.The RANTTAS Investigators: Faught E et.al. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS).Stroke 27:1453-1458, 199652.Chu WJ, Hetherington HP, Kuzniecky RI, Vaughan JT, Twieg DB, Faught E, Gilliam FG, Hugg JW, Elgavish GA. Is the intracellular pH different from normal in the epileptic focus of temporal lobe epilepsy patients? A 31P NMR study. Neurology,47:756-760, 199653.Kuzniecky R, Gilliam F, Morawetz R, Faught E, Palmer C, Black L. Occipital lobe developmental malformations and epilepsy: clinical spectrum, treatment and outcome. Epilepsia 38(2):175-181, 199754.Gilliam F, Kuzniecky R, Faught E, Black L, Carpenter G, Schrodt R. Patient-validated content of epilepsy-specific quality-of-life measurement.Epilepsia 38:233-236, 199755.Gilliam F, Wyllie E, Kashden J, Faught E, Kotagal P, Bebin M, Wise M, Comair Y, Morawetz R, Kuzniecky R. Epilepsy surgery outcome: comprehensive assessment in children. Neurology 48:1368-1374, 1997, Epilepsia 38:233-236, 199756.Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia 38(April 1):24-27, 199757.Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial-onset seizures: retrospective survey of open-label. Epilepsia 38(Suppl 1):S34-S36, 199758.Laich E, Kuzniecky R., Mountz J, Liu H, Gilliam F, Bebin M, Faught E. Supplementary sensorimotor area epilepsy: seizure localization, cortical propagation and subcortical activation pathways using ictal SPECT. Brain 1997; 120:855-86459.Ho S, Kuzniecky R, Gilliam F, Faught E, Bebin M, Morawetz R. Congenital porencephaly and hippocampal sclerosis. Neurology 49:1382-1388, 199760.Kuzniecky R, Bilir E, Gilliam F, Faught E, Palmer C, Morawetz R, Jackson G. Mutimodality MRI in mesial temporal sclerosis: relative sensitivity and specificity. Neurology 49:774-778, 199761.Kuzniecky R., Guthrie B, Mountz J, Bebin M, Gilliam F., Faught E. Intrinsic epileptogenesis of hypothalamic hamartomas in gelastic epilepsy. Annals of Neurology 42:60-67, 199762.Kuzniecky R, Hetherington H, Pan J., Hugg J., Palmer C., Gilliam F., Faught E, Morawetz R. 4.1 tesla proton spectroscopic imaging in patients with malformations of cortical development and epilepsy.Neurology; 48:1018-1024, 199763.Gilliam F, Bowling S, Bilir E, Thomas J, Faught E, Morawetz R, Hugg J, Kuzniecky R. Association of combined MRI, interictal EEG, and ictal EEG results with outcome and pathology after temporal lobectomy. Epilepsia 38(12):1315-1320, 199764.Ho S, Kuzniecky R, Gilliam F, Faught E, Bebin M, Morawetz R. Congenital porencephaly: MRI features: relation to hippocampal sclerosis. AJNR 19:135-141, 199865.Ho S, Kuzniecky R, Gilliam F, Faught E, Morawetz R. Temporal lobe epilepsy developmental malformations and epilepsy: dual pathology and bilateral hippocampal abnormalities. Neurology 50:748-754, 199866.Sawrie SM, Martin RC, Gilliam FG, Roth DL, Faught E, Kuzniecky R. Contribution of neuropsychological data to the prediction of temporal lobe epilepsy surgery outcome. Epilepsia 39:319-325, 199867.Johnston KC , Li JY, Lyden PD, Hanson SK, Feasby TE, Adams RJ, Faught RE Jr, Haley EC Jr. Medical and neurological complications of ischemic stroke.experience from the RANTTAS trial. Stroke 29(2):447-453, 199868.Kuzniecky R, Hugg JW, Hetherington H, Butterworth E, Bilir E, Faught E, Gilliam F. Relative utility of 1H spectroscopic imaging and hippocampal volumetry in the lateralization of mesial temporal lobe epilepsy. Neurology 51:66-71, 199869.Kuzniecky R, Hetherington H, Ho S, Pan J, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 51:627-629, 199870.Bilir E, Craven W, Hugg J, Gilliam F, Martin R, Faught E, Kuzniecky R. MRI-volumetric measurement of the limbic system: anatomic determinants. Neuroradiology 40:138-144, 199871.Cereghino JJ, Mitchell WG, Murphy J: E Faught and the North American Diastat Study Group. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. Neurology 51:1274-1282, 199872.Faught E. Juvenile myoclonic epilepsy without myoclonus. Clin Lessons in Epilepsy 1:9-11, 199873.Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, Handforth A, Faught E, Calabrese VP, Uthman BM, Ramsay RE, Mamdani MB. A comparison of four treatment for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med 339:792-798, 1998 (REFERENCE LEADER: referenced 915 times as of June, 2019)74.Ho SS, Consalvo D, Gilliam F, Faught E, Bilir E, Morawetz R, Kuzniecky RI. Amygdala atrophy and seizure outcome after temporal lobe epilepsy surgery.Neurology 51:1502-1504, 199875.Martin RC, Sawrie SM, Roth DL, Gilliam FG, Faught E, Morawetz RB, Kuzniecky RI. Individual memory change after anterior temporal lobectomy: a base rate analysis using regression-based outcome methodology. Epilepsia 39:1075-1082, 199876.Martin R, Gilliam F, Kilgore M, Faught E, Kuzniecky R. Improved health care utilization following video-EEG-confirmed diagnosis of nonepileptic psychogenic seizures. Seizure 7:385-390, 199877.Gilliam F, Vazquez B, Sackellares JC: Faught E, et al. An active-control trial of lamotrigine monotherapy for partial seizures.Neurology 51:1018-1025, 199878.Dreifuss FE, Rosman, Cloyd J, Kuzniecky R, (Faught E, et al). A comparison of rectal diazepam gel and placebo for acute repetitive seizures. New England Journal of Medicine 338:1869-1875, 199879.Martin R, Bilir E, Roth D, Hugg J, Gilliam F, Faught E, Kuzniecky R. MRI extrahippocampal volumes and visual memory: correlations independent of MRI hippocampal volumes in temporal lobe epilepsy patients. J Int NeuropsycholSoc 5(6):540-548, 199980.Saver JL, Johnston KC, Home D: The RANTTAS Investigators (Faught E, et al). Infarct volume as a surrogate or auxiliary outcome measure in ischemic stroke clinical trials.Stroke 30:293-298, 199981.Khan A, Faught E, Gilliam F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure 8(4):235-237, 199982.Geyer J, Gilliam F, Bilir E, Faught RE, Kuzniecky R. Significance of interictal temporal lobe delta activity for localization of the primary epileptogenic region. Neurology 52:202-205, 199983.Geyer J, Faught E, Drury I. Post-ictal nose-rubbing in the diagnosis, lateralization, and localization of seizures. Neurology 52:743-745, 199984.Dean C, Mosier M, Penry K: Faught E et al. Dose-response study of vigabatrin as add-on therapy in patients with complex partial seizures.Epilepsia 40:74-82, 199985.Biton V, Montouris GD, Ritter F et al: Faught E and the Topiramate YTC Study Group. A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 52:1330-1337, 199986.French J, Smith M, Faught E. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 52(8):1540-1545, 199987.Kuzniecky R, Bilir E, Gilliam F, Faught E. Quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy. Neurology 53(3):496-501, 199988.Kriel RL, Cloyd JC, Pellock JM, Mitchell WG, Cereghino JJ, Rosman NP, Dreifuss FE, Faught E, et al. Rectal diazepam gel in the treatment of children with acute repetitive seizures. Pediatric Neurology, 20(4):282-288, 199989.Schachter SC, Vazquez B, Fisher RS, Laxer KD, Montouris GD, Combs-Cantrell DT, Faught E, Willmore LJ, Morris GL, Ojemann L, Bennett D, Messenbrink P, D’Souza J, Kramer L. Oxcarbazepine: a double-blind, randomized, placebo-controlled, monotherapy trial for partial seizures. Neurology 52(4):732-737, 199990.Martin R, Kuzniecky R, Ho S, Hetherington H, Pan J, Sinclair K, Gilliam F, Faught E. Cognitive effects of topiramate, gabapentin, and lamotrigine in healthy young adults.Neurology 52:321-327, 199991.Kuzniecky R, Ho S, Martin R, Faught E, Morawetz R, Palmer C, Gilliam F. Temporal lobe developmental malformations and hippocampal sclerosis: epilepsy surgical outcome. Neurology 52:479-484, 199992.Faught E. Lamotrigine for startle-induced seizures. Seizure 8(6):361-363, 199993.McLean MJ, Morrell MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus-Miller L, Bernstein P, Rose-Legatt A. Safety and tolerability of gabapentin as adjunctive therapy in a large multicenter study. Epilepsia 40(7):965-972, 199994.Faught E, Morris G, Jacobson M, French J, Harden C, Montouris G, Rosenfeld W. Adding lamotrigine to valproate: incidence of rash and other adverse effects. Postmarketing Antiepileptic Drug Survey (PADS) Group.Epilepsia 40(8):1135-1140, 199995.Gilliam F, Kuzniecky R, Martin R, Meador K, Morawetz R, Viikinsalo M, Faught E. Patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy. Neurology 53(4):687-694, 199996.Dean C, Mosier M, Penry K: Faught E et al. Dose-response study of vigabatrin as add-on therapy in patients with uncontrolled complex partial seizures. Epilepsia 40:74-82, 199997.Kuzniecky R, Hetherington H, Ho S, Pan J, Martin R, Gilliam F, Hugg J, Faught E. Topiramate increases cerebral GABA in healthy humans. Neurology 51:627-629, 199998.Sawrie SM, Martin RC, Kuzniecky R, Faught E, Morawetz R, Jamil F, Viikinsalo M, Gilliam F. Subjective versus objective memory change after temporal lobe epilepsy surgery. Neurology 53(11):1511-1517, 199999.Martin R, Sawrie S, Hugg J, Gilliam F, Faught E, Kuzniecky R. Cognitive correlates of 1H MRSI-detected hippocampal abnormalities in temporal lobe epilepsy. Neurology 53(9):2052-2058, 1999100.Kuzniecky R, Hugg J, Hetherington H, Martin R, Faught E, Morawetz R, Gilliam F. Predictive value of 1H MRSI for outcome in temporal lobectomy. Neurology 53(4):694-698, 1999101.Martin R, Ho S, Gilliam F, Faught E, Morawetz R, Kuzniecky R. Cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis. Neurology 53(4):709-715, 1999102.Faught E. Sudden onset of epilepsia partialis continua. Clin Less in Epilepsy 2:6-7, 1999103.Ness TJ, Fillingim RB, Randich A, Backensto EM, Faught E. Low intensity vagal nerve stimulation lowers human thermal pain thresholds. Pain 86(1-2):81-85, 2000104.Tamura T, Aiso K, Johnston KE, Black L, Faught E. Homocysteine, folate, vitamin B-12, and vitamin B-6 in patients receiving antiepileptic drug monotherapy. Epilepsy Research 40(1):7-15, 2000105.Chu WJ, Kuzniecky RI, Hugg JW, Abou-Khalil B, Gilliam F, Faught E, Hetherington temporal lobe epilepsy: an intent-to-treat analysis. Epilepsia 41(8):963-966, 2000112.Limdi N, Faught E. The safety of rapid intravenous valproate.Epilepsia 41(10):1342- HP. Statistically driven identification of focal metabolic abnormalities in temporal lobe epilepsy with corrections for tissue heterogeneity using H MRSI. Magn Reson Med 43(3):359-367, 2000106.Gilliam F, Steinhoff BJ, Bitterman HJ, Kuzniecky R, Faught E, Abou-Khalil B. Adult myoclonic epilepsy: a distinct syndrome of idiopathic generalized epilepsy. Neurology 55(7):1030-1033, 2000107.Bengtson M, Martin R, Sawrie S, Gilliam F, Faught E, Morawetz R, Kuzniecky R. Gender, memory, and hippocampal volumes: relationships in temporal lobe epilepsy. Epilepsy & Behavior 1:112-119, 2000108.Martin R, Bilir E, Roth D, Hugg J, Gilliam F, Faught E, Kuzniecky R: MRI extrahippocampal volumes and visual memory: correlations independent of MRI hippocampal volumes in temporal lobe epilepsy patients. J Inter Neuropsychol 5:540- 548, 2000109. Faught E, Limdi N. The safety of intravenous valproate. Epilepsia 2000; 41(10): 1342-5109.Sawrie S, Martin, R, Hugg J, Gilliam F, Faught RE, Sinclair K, Maton B, Kuzniecky R. Visual confrontation naming and hippocampal function: A neural network study using quantitative 1H magnetic resonance spectroscopy. Brain 123:770-780, 2000110.Sawrie S, Martin R, Faught E, Maton B, Hugg J, Kuzniecky R. Nonlinear trends in hippocampal metabolic function and verbal memory: evidence of cognitive reserve in temporal lobe epilepsy? Epilepsy &Behavior 1:106-111, 2000111.Gilliam F, Faught E, Martin R, Bowling S, Bilir E, Thomas J, Morawetz R, Kuzniecky R. Predictive value of MRI-identified mesial temporal sclerosis for surgical outcome in 1345, 2000113.Morrell MJ, McLean MJ, Willmore LJ, Privitera MD, Faught RE, Holmes GL, Magnus-Miller GL, Podolnick PB, Rose-Legatt HA. Efficacy of gabapentin as adjunctive therapy in a large multicenter study. The Steps Study Group. Seizure 9:241-248, 2000114.Martin RC, Sawrie SM, Edwards R, Roth DL, Faught E, Kuzniecky RI, Morawetz RB, Gilliam FG. Investigation of executive function change following anterior temporal lobectomy: selective normalization of verbal fluency. Neuropsychology 14(4):501-508, 2000. 116.Lawn N, Londono A, Gilliam F, Faught E, Kuzniecky R: Occipital parietal epilepsy and congenital developmental abnormalities. Epilepsia 41(12):1546-1553, 2000.117. Laxer K, Blum D, Abou-Khalil BW, Morrell MJ: Faught E et. al. (Ganaxolone Presurgical Study Group). Assessment of ganaxolone’s anticonvulsant activity using a randomized, double-blind, presurgical trial design. Epilepsia 41(9): 1187-1194, 2000 115.Martin RC, Sawrie SM, Gilliam FG, Kuzniecky RI, Faught E. Wisconsin Card Sorting performance in patients with temporal lobe epilepsy: clinical and neuroanatomical correlates. Epilepsia 41(12):1626-1632, 2000.118.Sawrie SM, Martin RC, Gilliam F, Knowlton R, Faught E, Kuzniecky R. Verbal retention lateralizes patients with unilateral temporal lobe epilepsy and bilateral hippocampal atrophy. Epilepsia 42(5):651-659, May 2001.119.Maton B, Gilliam F, Sawrie S, Martin R, Faught E, Kuzniecky R: Correlation of scalp EEG and 1H-MRS metabolic abnormalities in temporal lobe epilepsy. Epilepsia 42(3):417-422, 2001.120.Tatum WO, French JA, Faught E, et al. Postmarketing experience with topiramate and cognition. Epilepsia 42(9):1134-1140, September 2001.121.Martin RC, Sawrie SM, Knowlton RC, Bilir E, Gilliam FG, Faught E, Morawetz RB, Kuzniecky R. Bilateral hippocampal atrophy: consequences to verbal memory following temporal lobectomy. Neurology 57(4):597-604, August 28, 2001.122.Martin R, Meador K, Turrentine L, Faught E, Sinclair K, Kuzniecky R, Gilliam F. Comparative cognitive effects of carbamazepine and gabapentin in healthy senior adults. Epilepsia 42(6):764-71, June 2001.123.Faught E, Ayala R, Montouris G, Leppik I and the Zonisamide 922 Trialy Group. Randomized controlled trial of zonisamide for the treatment of refractory partial-onset seizures. Neurology , 57:1774-1779, 2001.124.Sawrie SM, Martin RC, Knowlton R, Faught E, Gilliam F, Kuzniecky R. Relationship among hippocampal volumetry, proton magnetic resonance spectroscopy, and verbal memory in temporal lobe epilepsy. Epilepsia 42(11):1403-1407, 2001125.Kuzniecky R, Palmer C, Hugg J, Martin R, Sawrie S, Morawetz R, Faught E, Knowlton R. Magnetic resonance spectroscopic imaging in temporal lobe epilepsy: neuronal dysfunction or cell loss? Arch Neurol 2001;58(12):2048-2053.126.Devinsky O, Vasquez B, Faught E, Leppik IE, Pellock JM, Schachter S, Alderfer V, Holdich TA. A double-blind placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following presurgical assessment. Seizure 11(6):371-376, Sep 2002.127.Martin RC, Kretzmer T, Palmer C, Sawrie S, Knowlton R, Faught E, Morawetz R, Kuzniecky R. Risk to verbal memory following anterior temporal lobectomy in patients with severe left-sided hippocampal sclerosis. Arch Neurol 2002;59(12):1895-1901.128.Martin R, Sawrie S, Gilliam F, Mackey M, Faught E, Knowlton R, Kuzniecky R. Determining reliable cognitive change after epilepsy surgery: development of reliable change indices and standardized regression-based change norms for the WMS-III and WAIS-III. Epilepsia 2002;43(12):1551-1558.129.Burneo JG, Faught E, Knowlton R, Morawetz R, Kuzniecky R. Weight loss associated with vagus nerve stimulation. Neurology 2002;59(3):463-464.130.Kuzniecky R, Ho S, Pan J, Martin, R, Gilliam F, Faught E, Hetherington H. Modulation of cerebral GAA by topiramate, lamotrigine, and gabapentin in healthy adults. Neurology 2002;58(3):368-372.131.Knowlton RC, Abou-Khalil B, Sawrie SM, Martin RC, Faught RE, Kuzniecky RI. In vivo hippocampal metabolic dysfunction in human temporal lobe epilepsy.Arch Neurol 2002;59(12):1882-1886.132.Burneo G, Montori VM, Faught E. Magnitude of the placebo effect in randomized trials of antiepileptic agents. Epilepsy and Behavior 2002;3:532-534.133.Cereghino JJ, Cloyd JC, Kuzniecky RI: Faught E and the North American Diastat Study Group. Rectal diazepam gel for treatment of acute repetitive seizures in adults.Arch Neurol 59(12):1915-1920, 2002 Dec.134.Burneo JG, Limdi N, Kuzniecky RI, Knowlton RC, Mendez M, Lawn N, Faught E, Welty TE, Prasad A. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy. Neurology135.Burneo JG, Arnold T, Palmer CA, Kuzniecky RI, Oh SJ, Faught E. Adult onset neuronal ceroid lipofuscinosis (Kufs’ disease) with autosomal dominant inheritance in Alabama. Epilepsia 44(6):841-846, 2003.153. Burneo JG, Faught E, Knowlton RC, et al. Temporal lobectomy in congenital porencephaly associated with hippocampal sclerosis. Arch Neurol 60(6):830-834, 2003155.Faught E. A steelworker with infrequent seizures.Epilepsy Behav 4(Suppl 2):39-41, 2003.156.Martin R, Vogtle L, Gilliam F, Faught E. Health-related quality of life in senior adults with epilepsy: what we know from randomized clinical trials and suggestions for future research. Epilepsy Behav. 2003 Dec; 4(6):626-34.157.Martin R, Burneo JG, Prasad A, Powell T, Faught E, Knowlton R, Mendez M. Kuzniecky R. Frequency of epilepsy in patients with psychogenic seizures monitored by video-EEG. Neurology 2003 Dec 23;61(12):1791-2.158.Kanner AM, Wuu J, Faught E, Tatum Wo IV, Fix A, French J: The PADS Investigators. A past psychiatric history may be a risk factor for topiramate –related psychiatric and cognitive adverse events. Epilepsy Behav. 2003 Oct;4 (5):548-52.159.Burneo JG, Bilir E, Faught E, Morawetz R, Knowlton RC, Martin R, Kuzniecky RI. Significance of fornix atrophy in temporal lobe epilepsy surgery outcome. Arch Neurol. 2003 Sep;60(9):1238-42.160.Prasad A, Kuzniecky RI, Knowlton RC, Welty TE, Martin RC, Mendez M, Faught RE. Evolving antiepileptic drug treatment in juvenile myoclonic epilepsy. Arch Neurol 2003 Aug;60(8):1100-5. 161.Burneo JG, Martin R; Powell T, Greenlee S, Knowlton RC, Faught RE, Prasad A, Mendez M, Kuzniecky RI. Teddy Bears: an observational finding in patients with non-epileptic events. Neurology 2003 Sep 9;61(5):714-5.162.Banos JH, Roth DL; Palmer C; Morawetz R; Knowlton R; Faught E, Kuzniecky R, Bilir E, Martin RC. Confirmatory factor analysis of the California verbal learning test in patients with epilepsy: relationship to clinical neuropathological markers of temporal lobe epilepsy. Neuropsychology 2004 Jan;18(1):60-8.163.Faught E, Matsuo FU, Schachter, et al. Long-term tolerability of lamotrigine: data from a 6-year continuation study. Epilepsy Behav, Feb 2004, 5(1) p31-6.164.Lawn N, Laich E, Ho S, Martin R, Faught E, Knowlton R, Morawetz R, Kuzniecky R. Eclampsia, hippocampal sclerosis, and temporal lobe epilepsy: Accident or association? Neurology 2004 Apr 27;62(8):1352-6.165.French JA, Kanner AM, Bautista J, et al: Faught E, et al. Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittees of the American Academy of Neurology/ American Epilepsy Society. Neurology 2004; Also published in Epilepsia, May 2004, 45(5)p410-23166.Banos JH, LaGory J, Sawrie S, Faught E, Knowlton R, Prasad A, Kuzniecky R, Martin RC. Self-report of cognitive abilities in temporal lobe epilepsy: cognitive, psychosocial, and emotional factors. Epilepsy Behav. 2004 Aug;5(4):575-9.167.Burneo JG, Knowlton RC, Faught E, Martin R, Sawrie S, Kuzniecky RI. Chronic temporal lobe epilepsy: spatial extent and degree of metabolic dysfunction studied with magnetic resonance spectroscopy (MRS). Epilepsy Res. 2004 Dec;62(2-3):119-24.168.Burneo JG, Black L, Knowlton RC, Faught E, Morawetz R, Kuzniecky RI. Racial disparities in the use of surgical treatment for intractable temporal lobe epilepsy. Neurology. 2005 Jan 11;64(1):50-4.169.Limdi NA, Shimpi AV, Faught E, Gomez CR, Burneo JG. Efficacy of rapid IV administration of valproic acid for status epilepticus. Neurol. 2005 Jan25;64(2):353-5. 170.Martin RC, Griffith HR, Faught E, Gilliam F, Mackey M, Vogtle L. Cognitive functioning in community dwelling older adults with chronic partial epilepsy. Epilepsia. 2005 Feb;46(2):298-303.171. LoGalbo A, Sawrie S, Roth DL, Kuzniecky R, Knowlton R, Faught E, Martin R. Verbal memory outcome in patients with normal preoperative verbal memory and left mesial temporal sclerosis. Epilepsy Behav. 2005 May; 6(3):337-41.172.Rowan AJ, Ramsay RE, Collins JF: Faught E et al (VA Cooperative Study Group 428). New onset geriatric epilepsy: a randomized study of gabapentin,lamotrigine, and carbamazepine. Neurology 2005; 64(11): 1868-1873.173.Martin R, Vogtle L, Gilliam F, Faught E. What are the concerns of older adults living with epilepsy? Epilepsy Behav. 2005 Sep;7(2):297-300.174. Burneo JG, Black L, Martin R. Devinsky O, Pacia S, Faught E, Vasquez B, Knowlton RC, Luciano D, Doyle W, Najjar S, Kuzniecky R. Race/ethnicity, sex, and socioeconomic status as predictors of outcome after surgery for temporal lobe epilepsy. Arch Neurol 2006; 63(8):1106-10175. Griffith HR, Martin RC, Bambara JK, Marson DC, Faught E. Older adults with epilepsy demonstrate cognitive impairments compared with patients with amnestic mild cognitive impairment. Epilepsy Behav. 2006 Feb;8(1):161-8. Epub 2005 Nov 2.176. Martin R, Griffith HR, Sawrie S, Knowlton R, Faught E. Determining empirically basedself-reported cognitive change: development of reliable change indices and standardized regression-based change norms for the multiple abilities self-report questionnaire in an epilepsy sample. Epilepsy Behav. 2006 Feb;8(1):239-45. Epub 2005 Dec 20.Welty TE, Faught E, Privitera MD. Step therapy is not appropriate for antiepileptic drugs. J Manag Care Pharm. 2006 Apr;12(3):269-70.Knowlton RC, Elgavish R, Howell J, Blount J, Burneo JG, Faught E, Kankirawatana P, Riley K, Morawetz R, Worthington J, Kurniecky R.Magnetic source imaging versus intracranial EEG in epilepsy surgery: a prospective study. Ann Neurol 2006; 59 (5):835- 42.McConley R, Martin R, Banos J, Blanton P, Faught E. Global/local scoring modifications for the Rey-Osterrieth complex figure: relation to unilateral temporal lobe epilepsy patients. J Internat Neuropsych Soc. 2006;12:383-90. Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Research 2006; 71: 89-95.Griffith HR, Martin RC, Bambara JK, Marson DC, Faught E. Older adults with epilepsy demonstrate cognitive impairments compared with amnestic mild cognitive impairment. Epilepsy andBehavior 2006: 8: 161-68.Burneo JG, Black L, Martin R, Devinsky O, Pacia S, Faught E, Vasquez B, Knowlton RC, Luciano D, Doyle W, Najjar S, Kuzniecky R. Race/ethnicity, sex, and socioeconomic status as predictors of outcome after surgery for temporal lobe epilepsy. Arch Neurol 2006; 63(8): 1106-10.Gilliam FG, Maton BM, Martin RC, Sawrie SM, Faught RE, Hugg JW, Viikinsalo M, Kuzniecky R. Hippocampal 1H-MRSI correlates with severity of depression symptoms in temporal lobe epilepsy. Neurology 2007; 68(5): 364-8.Bambara JK, Griffith HR, Martin RC, Faught E, Wadley VG, Marson DC . Medical decision-making abilities in older adults with chronic partial epilepsy. Epilepsy Behav 2007; 10(1): 63-8Limdi NA, Knowlton RK, Cofield SS, Ver Hoef LW, Paige AL, Dutta S, Faught E. Safety of rapid intravenous loading of valproate. Epilepsia 2007; 48(3):478-83.Burneo JG, Villaneuva V, Knowlton RC, Faught RE, Kuzniecky RI. Kaplan-Meier analysis on seizure outcome after epilepsy surgery: Do gender and race influence it? Seizure 2007.Dutta S, Faught E, Limdi N. Valproate protein binding following rapid intravenous administration of high doses of valproic acid in patients with epilepsy. J Clin Pharm Therap 2007; 32: 1-7Griffith HR, Martin RC, Bambara JK, Faught E, Vogtle LK, Marson DC. Cognitive functioning over 3 years in community dwelling older adults with chronic partial epilepsy. Epilepsy Res 2007; 74:91-6.Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM: Faught E and the 205 Study Group. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology 2007; 68:1197-1204.Faught E, Duh MS, Weiner JR, Guerin A, Cunnington MC. Nonadherencce to antiepileptic drugs and increased mortality. Findngs from the RANSOM study. Neurology 2008; 71(20):1572-8.Faught E, Holmes GL, Rosenfeld WE, Novak G, Neto W, Greenspan A, Schmitt J, Yuen E, Reines S, Haas M. Randomized, controlled dose-ranging trial of carisbamate for partial-onset seizures.Neurology 2008; 71(20): 1586-93.Faught E, Weiner J, Guerin A, Cunnington MC, Duh MS. Impact of nonadherence to antiepileptic drugs on healthcare utilization and costs: findings from the RANSOM study. Epilepsia 2009; 50(3): 501-9.Griffith HR, Martin R, Andrews S, Paige AL, Ware J, Faught E, Welty T. The safety and tolerability of galantamine in patients with memory difficulties. Epilepsy Behav 2008; 13: 376-80Knowlton RC, Elgavish RA, Limdi N, Bartolucci A, Ojha B, Blount J, Burneo JG, Ver Hoef L, PaigeAL, Faught E, Kankirawatana P, Riley K, Kuzniecky R. Functional imaging I: Relative predictive value of intracranial electroencephalography. Ann Neurol2008; 64(1):25-34.Knowlton RC, Elgavish RA, Bartolucci A, Ojha B, Limdi N, Blount J, Burneo JG, Ver Hoef L, Paige AL, Faught E, Kankirawatana P, Riley K, Kuzniecky R. Functional imaging II: Prediction of epilepsy surgery outcome. Ann Neurol 2008; 64(1): 35-41.McConley R, Martin R, Palmer CA, Kuzniecky R, Knowlton R, Faught E.Rey Osterreith complex figure test spatial and figural scoring: relations to seizure focus and hippocampal pathology in patients with temporal lobe epilepsy. Epilepsy Behav 2008; 13(1): 174-7.Dewolfe JL, Knowlton RC, Beasley MT, Cofield S, Faught E, Limdi N. Hyperammonemia following intravenous valproate loading. Ep Res 2009; 85(1): 65-71.Knowlton RC, Razdan S, Limdi NA, Elgavish RA, Killen J, Blount J, Burneo JG, Ver Hoef L; Paige L, Faught E, Kankirawatana P, Riley K, Kuzniecky, R. Effect of magnetic source imaging on intracranial electrode placement for epilepsy surgery. Ann Neurol. 2009; 65(6):716-723.Chung S, Sperling MR, Biton V (The SP754 Study Group, Faught E et. al.) Lacosamide as adjunctive therapy for partial-onset seizures. A randomized controlled trial. Epilepsia 2010; 51(6): 958-967Ramsay E, Faught E, Krumholz A, Naritoku D, Privitera M, et. al: The CAPSS-272 Study Group. Efficacy, tolerability, and safety of rapid initiation of topiramate versus phenytoin in patients with new-onset epilepsy: a randomized double-blind clinical trial. Epilepsia 2010; 52(8): 1-8.Benbadis SR, Faught RE, Sirven J, Slater JD, Sperling MR, Hirsch LJ. The pervasive influence of conflicts of interest: a personal perspective. Neurology 2010; 75(22):2045-6. PMID 21158001.Helmers S, Duh MS, Guerin A, Sarda SP, Samuelson TM, Bunker MT, Olin BD, Jackson SD, Faught E. Clinical and economic impact of vagus nerve stimulation in patients with drug-resistant epilepsy. Epilepsy and Behavior 2011. (accepted for publication 17 July 2011, manuscript EB-11-241R-1).Pellock JM, Faught E, Sergott RC, Shields WD, Burkhart GA, Krauss GL, Foroozan R, Wesche DL, Weinberg MA. Registry initiated to characterize vision loss associated with vigabatrin therapy. Epilepsy Behav. 2011;22:710?7.Helmers, S, Faught E. Ms. Ref. No.: ?EJPN-D-11-00237R1?Title: Clinical outcomes, quality of life, and costs associated with implantation of vagus nerve stimulation therapy in pediatric patients with drug-resistant epilepsy. ?European J Paediatric Neurology, 2012Faught E, Richman J, Martin RC, Funkhouser EM, Foushee Jr HF, Kratt PP, Kim Y, Clements K, Cohen NJ, Adoboe D, Knowlton R, Pisu M. Incidence and prevalence of epilepsy among older United States Medicare beneficiaries. Neurology 2012; 78(7): 448-53.Burden of uncontrolled epilepsy in patients requiring an emergency room visit or hospitalization. Paradis E, Parise H, Lafeuille M, Bowers B, Duh MS, Lefebvre P, Faught E. Neurology 2012; 79:1908-1916.Paradis PE, Parise H, Duh MS, Bowers BW, Faught E. Incremental clinical and economic burden of uncontrolled partial-onset seizures in a privately-insured population. Value in Health 2012; 15(4): 4-10.Pisu M, Richman JS, Martin RC, Kim Y, Kratt P, Clements K, Funkhouser E, Knowlton R, Faught E. Diagnostic tests and neurology care for Medicare beneficiaries with seizures: differences across racial groups. Medical Care 2012; 50(8): 730-6.Pisu M Kratt P, Faught E, Martin RC, Kim Y, Clements K, Knowlton R, Funkhouser E, Richman JS. Geographic variation of epilepsy for older Americans: how close to the geographic variation of stroke? Epilepsia 2012; 53(12): 2186-93Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with lacosamide: results from a Phase III open-label extension trial. Epilepsia 2012; 53(3): 521-8.Cadieux-Dion M, Andermann E, Lachance-Touchette P, Ansorge O, Meloche C, Barnabe’ A, Kuzniecky RI, Andermann F, Faught E, Leonberg S, Damiano JA, Berkovic SF, Rouleau GA, Cosette P. Recurrent mutations in DNAJC5 cause autosomal dominant Kufs disease. Clinical Genetics 2013; 83(6): 571-5Vossler DG, Morris GL, Harden CL, Montouris G, Faught E, Kanner AM, Fix A, French JA. Tiagabine in clinical practice. Effects on seizure control and behavior. Epilepy and Behavior 2013, 28(2): 211-216. PMID 23770680Faught E. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opinion on Investigational Drugs 2014, 23(1):107-13. PMID 24147649Ettinger AB, Good MB, Manjunath R, Faught RE, Bancroft T. The relationship of depression to adherence to antiepileptic drugs. Epilepsy and Behavior 2014; 36: 138-43. PMID 24926942Sperling MR, Rosenow F, Faught E, Hebert D, Doty P, Isojarvi J. Efficacy of lacosamide by focal seizure type. Epilepsy Res 2014; 108(8):1392-8. PMID25082395Martin RC, Faught E, Richman J, Funkhouser E, Kim Y, Clements K, Pisu M. Psychiatric and neurologic risk factors for incident cases of new-onset epilepsy in older adults: data from U.S. Medicare beneficiaries. Epilepsia 2014; 55(7): 1120-7. PMID 24902475..Faught E, Helmers SL, Begley CD, Thurman DJ, Dilley C, Clark C, Fritz P. Newer antiepileptic drug use and other factors decreasing hospital encounters. Epilepsy Behav 2015; 45: 169-75. Leeman-Markowski BA, Smart OL, Faught RE, Gross RE, Meador KJ. Cessation of gamma activity in the dorsomedial nucleus associated with loss of consciousness during focal seizures. Epilepsy Behav 2015; 51: 215-20. PMID: 26295448Helmers SL, Thurman DJ, Durgin TL, Pai AK, Faught E. Descriptive epidemiology of epilepsy in the U.S. population: A different approach. Epilepsia 2015; 56(6): 942-8 PMID 2591003Krauss G, Faught E, Foroozan R, Pellock JM, Sergott RC, Shields DS, Ziemann A, Dribinsky Y, Lee D, Torri S, Othman F, Isojarvi J. Sabril registry 5-year results: clinical p[rofiles of adult patients treated with vigabatrin. Epilepsy Behav, 2016; 56:15-9. PMID:26807550.Kim H, Thurman D, Durgin T, Faught E, Helmers S. Estimating incidence and prevalence in the US pediatric population using nationwide health insurance claims data., J Child Neurol 2016; 31: 743-9. PMID: 26719495Gupta S, Kwan P, Faught E, Tsong W, Forsythe A, Rivlin P. Understanding the burden of idiopathic generalized epilepsy in the United States, Europe, and Brazil: An analysis from the National Health and Wellness Survey. Epilepsy Behav 2016; 55:146-56. PMID: 26773686Drane DL, Ojemann, JG, Kim MS, Gross RE, Miller JW, Faught RE Jr, Loring DW. Interictal epileptiform discharge effects on neuropsychological assessment and epilepsy surgical planning. Epilepsy Behav 2016; 56: 131-8. PMID: 26874864Pellock JM, Faught E, Foroozan R, Sergott RC, Shields WD, Ziemann A, Lee D, Dribinsky Y, Torri S, Othman F, Isojarvi JU. Which children receive vigabatrin? Characteristics of pediatric patients enrolled in the mandatory FDA registry. Epilepsy Behav 2016; 18: 60:174=80. PMID: 27208827Martin RC,?Faught E, Szaflarski JP, Richman J, Funkhouser E, Piper K, Juarez L, Dai C, Pisu M. What does the U.S. Medicare administrative claims database tell us about initial antiepileptic drug treatment for older adults with new-onset epilepsy?Epilepsia, 2017. 548-557 PMID: 28176298.Piper K, Richman J,?Faught E, Martin R, Funkhouser E, Szaflarski JP, Dai C, Juarez L, Pisu M. Adherence to antiepileptic drugs among diverse older Americans on Part D Medicare. Epilepsy and Behavior 2017; 66: 68-75. PMID 28038389Faught E, Laliberté F, Wang Z, Barghout V, Haider B, Lejeune D, Germain G, Choi J, Wagh A, Duh MS. Healthcare resource utilization before and after perampanel initiation among patients with epilepsy in the United States. Epilepsia 2017, 58:1742-78, PMID 28741690.Pisu M, Richman J, Martin R, Funkhouser E, Dai C, Juarez L, Szaflarski JP, Faught E. Quality of antiepileptic treatment among older medicare beneficiaries with epilepsy a retrospective claims data analysis. Medical Care 2017; 55(7): 677-83. PMID 28437319.Szaflarski JP, Martin RC, Faught E, Funkhouser E, Richman J, Piper K, Juarez L, Dai C, Pisu M. Quality indicator for epilepsy treatment 15 (QUIET-15): intervening after recurrent seizures in the elderly. Epilepsy Behav 2017; 70:253-8; PMID 28412154.Gupta S, Ryvlin P,?Faught E, Tsong W, Kwan P. Understanding the burden of focal epilepsy as a function of seizure frequency in the United States, Europe, and Brazil .Epilepsia Open. 2017 Mar 27;2(2):199-213. doi: 10.1002/epi4.12050. eCollection 2017 Jun. PMID 29588949Bainbridge J, De Backer M, Eckhardt K, Tennigkeit F, Bongardt S, Sen D, Werhahn KJ, Shaibani A,?Faught E.Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain. Epilepsia Open 2017 Sep 11;2(4):415-423. doi: 10.1002/epi4 .PMID 29588972Halford JJ, Sperling MR, Nair DR, Dlugos DJ, Tatum WO, Harvey J, French JA, Pollard JR, Faught E, Noe KH, Henry TR, Jetter GM, Lie OV, Morgan LCd, Girouard MR, Cardenas DP, Whitmire LE, Cavazos JE. An EMG-based detection devide for tonic-clonic seizures. Epilepsia 2017; Nov;58(11):1861-1869. doi: 10.1111/epi.13897. Epub 2017 Oct 5. PMID 28980702.Faught E, Szaflarski JP, Martin RC, Funkhuser E, Richman J, Piicsu M. Risk of pharmacokinetic interactions among older epilepsy patients and factors associated with risk. Epilepsia 2018. Mar;59(3):715-723. doi: 10.1111/epi.14010. Epub 2018 Feb 7PMID 2941134 Kleen JK, Scott RC, Holmes GL, et al. Hippocampal interictal spikesdisrupt cognition in rats. Ann Neurol 2010;67:250–257.4. Zhou JL, Lenck-Santini PP, Zhao Q, et al. Effect of interictal spikes onsingle-cell firing patterns in the hippocampus. Epilepsia 2007;48:720–731.5. Urrestarazu E, Jirsch JD, LeVan P, et al. High-frequency intracerebralEEG activity (100–500 Hz) following interictal spikes. Epilepsia2006;47:1465–147Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis.Faught E. Helmers S, Thurman D, Kim H, Kalilani L. Patient characteristics and treatment patterns in patients with newly diagnosed epilepsy: A US database analysis. Epilepsy Behav 2018 Jun 12;85:37-44. doi: 10.1016/j.yebeh.2018.05.019. [Epub ahead of print] PMID 29906700Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, Hirtz D, Nespeca M, Gidal B,?Faught E, FrenchPractice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs II: Treatment-resistant epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, Hirtz D, Nespeca M, Gidal B,?Faught E, French J. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.Neurology. 2018 Jun 13. pii: 10.1212/WNL.0000000000005755. doi: 10.1212/WNL.0000000000005755. [Epub ahead of print] PMID 29898971Kanner AM, Ashman E, Gloss D, Harden C, Bourgeois B, Bautista JF, Abou-Khalil B, Burakgazi-Dalkilic E, Llanas Park E, Stern J, Hirtz D, Nespeca M, Gidal B,?Faught E, French J. Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of refractory epilepsy: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Epilepsy Society.Neurology. 2018 Jun 13. pii: 10.1212/WNL.0000000000005755. doi: 10.1212/WNL.0000000000005755. [Epub ahead of print] PMID 29898974 Kalilani L, Faught E, Kim H, Burudpakdee C, Seetasith A, Laranjo S,Friesen D, Haeffs K, Kiri V, Thurman D. Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US. Neurology 2019; 92(19): e2197-2208. PMID 30971487 Kim H, Kalilani L, Thurman DJ, Faught E. Antiepileptic drug treatment patterns in women of childbearing age with epilepsy:?US database analysis?JAMA Neurology 2019;. PMID 30933252. Pisu M, Richman J, Szaflarski JP, Funkhouser E, Dai C, Juarez L,?Faught E, Martin RC. High health care costs in minority groups of older US Medicare beneficiaries with epilepsy. Epilepsia. 2019 Jul;60(7):1462-1471. doi: 10.1111/epi.16051. Epub 2019 Jun PMID:31169918 Thurman D, Faught E, Helmers S, Kim H, Kalilani L. New-onset lesional and nonlesional epilepsy in the US population: Patient characteristics and patterns of antiepileptic drugs use. Epilepsy Res. 2019 Nov;157:106210. doi: 10.1016/j. Epub 2019 Sep 25. PMID: 31605878 Drane D, Willie J, Qiu D, Stern M, Voets N, Pedersen N, Mills S, Ikanga J, Staikova E, Kadom N, Saindaine A, Faught E, Meador KJ, Gross RE. Prediction of naming outcome in open versus laser temporal lobe surgery for medial temporal lobe epilepsy. 241.Dhakar M, Thurman DJ, Haider HA, Rodriguez-Ruiz A, Jette N, Faught E. Thirty-day readmission after sratus epilepticus in the United States: Insights from the nationwide readmission database. Accepted for publication in Epilepsy Research, 2020.242. Gupta K, Dickey AS, Hu R, Faught E, Willie JT. Robot assisted surgery with MRI-guided LITT of the anterior, lateral, and medial temporal lobe for temporal lobe epilepsy.Frontiers in Neurology, epub online 27Nov 2020. articles and editorials:Faught E. Current management of atherosclerotic stroke.Ala J Med Sci 24:54-58, 1987Nepomuceno C, Faught E, Langford K. Diagnosis and management of low back pain.Ala J Med Sci 25:430-435, 1988Faught E. Current role of electroencephalography in cerebral ischemia.Stroke 24:609-613, 1993Faught E, Photosensitive epilepsy. International J Pediatrics 8:262-266, 1993Faught E. Diagnosis and classification of epileptic seizures.Fed. Practitioner 13:25-28,1996Faught E. Lamotrigine monotherapy in patients with refractory partial-onset seizures. Proc. Royal Soc. Med, Intl. Congress and Symp. Series No. 214:41-46, 1996Olsen RW, Avoli M and the Focus on Epilepsy III Symposium (Whistler, B.C.); E Faught et al. GABA and epileptogenesis.Epilepsia 38:399-407, 1997Faught E. Reflex seizures. Epilepsy Minifellowship Lecture Series monograph, Bowman Gray School of Medicine, Wake Forest University, 1997Faught E. Clinical studies of topiramate. Drugs of Today 35:49-57, 1999Gilliam F, Kuzniecky R, Faught E. Ambulatory EEG monitoring (Review). J Clin Neurophysiol 16(2):111-115, 1999Faught E. Epidemiology and drug treatment of epilepsy in elderly people (Review).Drugs and Aging 15(4):255-269, 1999Faught E, Pellock JM. The challenge of treatment selection for epilepsy.Epilepsia 42(Suppl 8):45, 2001.Faught E. Collective data supports efficacy at multiple subpial transection. Epilepsy Currents 2(4): 108, 2002Faught E. Clinical trials for treatment of primary generalized epilepsies. Epilepsia 44(Suppl 7):44-50, 2003.Faught, E. Clinical presentations and phenomenology of myoclonus..Epilepsia.2003;44 Suppl 11: 7-12.Faught E. Topiramate: a viewpoint by Edward Faught. CNS Drugs. 2003:17(13):993-4.Faught E. Treatment of refractory generalized epilepsy. Reviews in Neurological Diseases 2004; 1 (Suppl 1): S1-S10.Faught E. Review of United States and European clinical trials of zonisamide in the treatment of refractory partial-onset seizures. Seizure 2004;135:559-65.Faught E. Attack of the pocket monsters: no lasting effects. Epilepsy Currents. 2004 Sept-Oct;4(5):198-9Faught E. Naming Seizures. Lancet 2005 Oct 8; 366 (9493):1251-2.Faught E. Pregabalin: the next new thing. Epilepsy Currents. 2005 Nov-Dec;5(6):217-9.Faught E. Monotherapy in adults and elderly persons. Neurology 2007, 69(24,Suppl 3):3-9Faught E. Epilepsy drugs: getting it right the first time. Lancet Neurology 2007; 6(6): 476-8 (Review and Reflection).Faught E. Topiramate in the treatment of partial and generalized epilepsy. Neuropsych Dis andTreatment 2007; 5: 1-13 (review).French JA, Faught E. Rational polytherapy. Epilepsia 2009; 50(suppl 8): 63-68 (review)Faught E. Ezogabine: A new angle on potassium currents. Epilepsy Currents 2011; July: 11: 1-15 (invited review).Faught E. Vigabatrin: review of United States experience. Acta Neurol Scand 2011Welty T, Faught E, Schmidt D. Be sure to read the fine print: the AHRQ report on epilepsy. Epilepsy Currents 2012Faught E. Antiepilepsy drug trials: the view from the clinic. Epileptic Disorders 2012;14 (2): 114-123Faught E. Adherence to antiepilepsy drug therapy. Ep and Behavior 2012, 25(2):297-302. Faught E. What does the future hold for patients with epilepsy? Lancet Neurol 2012; 11:298-300 (Review and Reflection).Faught E, Tatum WO. Trigeminal stimulation: a superhighway to the brain? (editorial) Neurology 2013; 80:7? 31. Faught E. Real spikes crash virtual cars. Epilepsy Currents 2016Faught E. Predicting the storm by watching the waves. Epilepsy Currents 2018 (Mar-Apr;18(2):99-100. doi: 10.5698/1535-7597.18.2.99. PMID 29643752Faught E. Finding a place for lacosamide in the ICU. Epilepsy Currents Oct 2018 in pressFaught E, Karakis I, Drane EL. The impact of interictal discharges on performance. Curr Neurol Neurosci Rep.?2018?Oct 8;18(12):88. doi: 10.1007/s11910-018-0892-Review. PMID: 302982404Faught E. Reality and hope in epilepsy therapy (editorial) Neurology 2018; 18(12): 88-90. PMID 30298240.Faught E. The cost of the second seizure: rethinking the treatment decision. Epilepsy Currents 2019; 19(2): 88-90. PMID 30955429Faught E. The winner by a nose: intranasal midazolam, Epilepsy Currents, 2019, Sep;19(5):310-312. doi: 10.1177/1535759719870508. Epub 2019 Aug 28.Welty TE, Chapman KE, Faught RE Jr, Kotsos E. Epilepsy Currents 2019; Nov-Dec issue, published online 21 October 2019. Response to request for comments from the United States Food and Drug Administration regarding cannabadiol preparations for epilepsy E. Measure for measure: measuring the value of measuring antiseizure medication levels. Epilepsy Currents, in press for June 2020Faught E. Reoperations for epilepsy surgery: How many times at bat? Epilepsy Currents, October, 2020Faught E. Alzheimer’s and EEGs. Epilepsy Currents, Jan 2021 (in press)Book Chapters (for professionals)Faught E: Quality of Life Issues. In: Willmore LJ (ed). Generalized Tonic-Clonic Seizures, Chicago: Discovery, 1995.Faught E: Felbamate. In: Wyllie E (2nd ed.). Treatment of Epilepsy, Principles and Practice, (2nd Ed.), Philadelphia: Lea and Febiger, 1996.Faught E. Felbamate. In: Wyllie E (ed). Treatment of Epilepsy: Principles and Practice (3rd ed), Philadelphia: Lea and Febiger, 2000.Faught E. Epilepsy in Adolescents and Adults. In: Rakel E, Bope ET (eds). Conn’s Current Therapy. New York: W.B. Saunders, 2001.Faught E, Limdi N. Adverse and Beneficial Side Effects of Antiepileptic Drugs. In: Ettinger A, Devinsky O (eds). Epilepsy and Concomitant Illness. NY: Butterworth-Heinemann, 2001.Faught E. Absence Seizures in an Adult In: Schachter S and Schmidt D (eds), 110 Puzzling Cases of Epilepsy, London: Martin Dunitz, 2002 (reprinted in 2nd edition, 2007).Faught E. Is it epilepsy or something else? Identifying seizures by behavioral characteristics. In Faught E (ed), The Year in Neurology 2004; Oxford: Clinical Publishing, 2004..Faught E, Limdi N. Oxcarbazepine. In: Shorvon S, Fish DR, Perucca E, Dodson WE, Olivier A (eds). The Treatment of Epilepsy (2nd ed) Oxford: Blackwell, 2004, pp.451-460.Faught E: Felbamate. In: Wyllie E (ed). Treatment of Epilepsy, Principles and Practice, (4th Ed.), Phila: Lea and Febiger, 2004.Faught E, DeGiorgio CM. Generalized Convulsive Status Epilepticus: Principles of Treatment. In: Wasterlain CG, Treiman DM (eds), Status Epilepticus. Mechanisms and Management. Boston: MIT Press, 2006.Faught E. Phenobarbital in Status Epilepticus. In: Wasterlain CG, Treiman DM (eds) ibid., 2006.DeGiorgio C, Faught E, Fujikawa D, Vespa P. Status Epilepticus. In: Noseworthy J (ed). Neurology. Philadelphia: Butterworth Heinemann, 2006.Faught E. Epilepsy case studies. Neurologic Clinics. 2006; 24(2): 291-307Welty TE, Faught E. Epilepsy. Ch.30 in Chisholm J (ed), Pharmacotherapy Princip. and Practice, NY: McGraw-Hill, 2006. Faught E, Glauser T. Topiramate. In: Engel J and Pedley T (eds). Epilepsy: A Comprehensive Textbook (2nd ed), Philadelphia: Lippincott Williams and Wilkins, 2009.Faught E, Blount J. Clinical Neurophysiol. II: Intracranial Electrodes. In: Wheless J, Willmore LJ, Brumback R (eds). Advanced Therapy in Epilepsy, Shelton, CT: Peoples: 2009.Faught E, Limdi N. Oxcarbazepine. In: Shorvon S. Fish DR. Perucca E, Dodson WE, Oivier A (eds.) The Treatment of Epilepsy (3rd Ed), Chapter 45. Oxford: Blackwell, 2009.Faught E. Antiepileptic Drugs, chapter in: Kuzniecky R (ed). Epilepsy 101: The Ultimate Guide for Patients and Families. New York: Medicus Press, 2010 () Faught E. Felbamate. In: Wyllie E (ed), Treatment of Epilepsy, Principles and Practice (5th ed), Phila: Lea and Febiger, 2010). Welty TE, Faught E. Epilepsy. Chapter 30 in Chisholm J (ed), Pharmacotherapy Principles and Practice., New York: McGraw-Hill, 2nd ed 2011. Faught E. Epilepsy After Sixty. Chapter 26 in Miller JW and Goodkin H (eds), Epilepsy in Clinical Practice, Oxford: Wiley, 2013.Faught E. Felbamate. In: Wyllie E (ed), Treatment of Epilepsy, Principles and Practice (6th ed) Phila: Lea and Febiger, 2014.Faught E, Kim H. Oxcarbazepine. In: Shorvon S, Perucca E, Engel J. The Treatment of Epilepsy (4th ed). Oxford: Blackwell, 2016.Welty TE, Faught E. Epilepsy. In Chisholm J (ed), Pharmacotherapy Principles and Practice., New York: McGraw-Hill, 3nd ed 2016. Dhakar M, Faught E. Felbamate In: Wyllie E (ed), Treatment of Epilepsy, Principles and Practice (7th ed) Phila: Lea and Febiger, 2019, in pressWelty TE, Faught E. Epilepsy. in Chisholm J (ed), Pharmacotherapy Principles and Practice., New York: McGraw-Hill, 3nd ed 2018. Gilliam F, Faught E. Adjunctive and Combination Therapies. In Engel J et al (eds) Epilepsy. Wolters-Kluwer, in press, 2020Welty TE, Faught E. Epilepsy. in Chisholm J (ed), Pharmacotherapy Principles and Practice., New York: McGraw-Hill, 4nd ed 2020 (in press)Faught E, Gloss D Topiramate. In: Engel J, (eds. Epilepsy: A Comprehensive Textbook (3d ed), Philadelphia: Lippincott Williams and Wilkins, 2021 (in press). Symposium ContributionsFaug.ht E, Handforth A. The EEG in Status Epilepticus. American Academy of Neurology Annual Meeting Symposium Syllabus, April, 1997Faught E. New Drugs. Course syllabus, Clinical Epilepsy I, American Academy of Neurology, May, 2000Faught E. Treatment gaps in epilepsy I: Diagnosis to treatment. International Epilepsy Congress, Bangkok, Thailand, June 2019.Books edited and written: 1. Benbadis SR, Faught E, Green RC. System Overload: A Book about Seizures. Atlanta: Pritchett-Hull, 1998. (for patients) 2. Faught E (ed). The Year in Neurology 2004. Oxford (UK): Clinical Publishing, 2005. Book reviews and Letters: Published Letters and Book Reviews1.Faught E, Hanna G. Complications following angiography.Neurology 31:498-499, April 1981. (letter)2.Faught E. Arteriographic findings and neurologic symptoms .Neurology 31:367-368, March 1982. (letter)3.Faught E. Indications for angiography in stroke. Neurology 34:1126-1127, 1984. (letter)4.Faught E. Neurology residency training programs.N Engl J Med 312(6):2380, 2/7/1985. (letter)5.Faught E. Seizure classification. Neurology 44 :1555, 1994. (letter)6.Faught E. “The Treatment of Epilepsy”, Wylie E (ed.) J Neurosurgery, 80:166, 1994. (book review)7.Faught E, Geerlings S. “Electroencephalography”, Hughes JS (ed.) Journal of Epilepsy, 1996. (book review)8.Faught E.“Epilepsy with Continuous Spike Waves in Sleep”, Beaumanoir J et al (eds) Epilepsia, 1996. (book review) 9.Schachter SC, Vazquez B, Fisher RS: E Faught et al. Oxcarbazepine in a monotherapy trial for partial seizures-placebo-controlled studies in neurology: where do they stop? Neurology 53:2211-2212, 1999 (letter)10.Ness TJ, Randich A, Fillingim R, Faught RE, Backensto E. Left vagus nerve stimulation suppresses experimentally-induced pain. Neurology 56(7):985-986, 2001. (letter)11. Faught RE. U.S. military reserves provide chance to help patients in need overseas. Am Med News 2/25/2002. (letter) 12.Faught E, Leppik I. Reply to Haruda FD. Randomized controlled trial of zonisamide for the treatment of partial-onset seizures. Neurology 58:1705, 2002. (letter)13. Faught E. “The Epilepsies”, Panayiotopoulos CP. Neurology 2007 (book review)14. Benbadis SR, Faught RE Jr., Hirsch L, Sperling M, Sirven J. Open letter and invitation to the pharmaceutical industry. “No, we cannot just present your slide deck.”Epilepsy Behav 2010 Sep. 15. Faught E. “Seizures and Epilepsy” (2nd ed), J Engel Jr, Neurology 2014, (book review) 16. Faught E. Clinical Neurophysiology Board Review., Gupta PK et al. J Clin Neurophys 2015 17. Martin RC, Faught E, Richman J, Funkhouser E, Pisu. In response: research using archival health care data: let the buyer beware. Epilepsia 2015; 56(2):322-3. PMID 2570847818. Faught E. Reflections on monotherapy trials for epilepsy. Letter and comment. Lancet Neurology, 2015; 15(7) 657-8. PMID 2730222519. Kalilani L,?Faught E, Thurman D, Kim H. Author response: Assessment and effect of a gap between new-onset epilepsy diagnosis and treatment in the US.Neurology. 2020 Mar 17;94(11):503. doi: 10.1212/WNL.0000000000009104 Manuals, videos, online material, and other teaching aids:For Physicians (Approved for Category I AMA CME credit)Faught E. Course Syllabi, Am.Acad of Neurol annual meetings 1994, 1997, 1998, 1999, 2000.Faught E. The Neurological Examination. Slide set and syllabus for course “Neurology for the Non- Neurologist”, AAN/Colorado Neurological Institute, used in four courses yearly, 1992-2000.Gilliam F, Kuzniecky R, Bebin M, Wise M, Black L, Faught E. The Acute Treatment of Seizures (videotape). Distributed by UAB Continuing Education and Parke-Davis, 1998.Faught E. Epilepsy in the Elderly. Slide set and syllabus for Sachdeo R (Director). Treatment of Epilepsy in the New Millennium, SCP Communications, 1999.Faught E. Transition to Maintenance Therapy. Slide set and syllabus for Holmes G (Director), Controlling Epilepsy, Postgraduate Institute for Medicine, 2003.Faught E. New Antiepileptics: Adverse Events and Their Impact on Quality of Life, for Faught E (Course Director). Traditional and New Antiepileptic Drugs (CME-approved monograph), Univ. of Florida, 2005. Faught E. Identifying and treating late-life seizures. In: Finding Answers to Critical Questions in Seizure Management (CME-accredited monograph). Univ. of Wisconsin, 2007.For NursesBlack L, Faught E, Kuzniecky R. Acute care for seizures. Video, distributed by UAB 2000.For Physicians - Internet MaterialFaught E. Review of the 2000 American Epilepsy Society Annual Meeting (Medscape, Inc).Faught E. Where is Memory? A review of material on the relationship of memory to epilepsy presented at the 2001 American Epilepsy Society Annual Meeting (Medscape, Inc).Faught E. AED Interactions. Medscape online CME course, 2016 (approved for Cat. I CME)For PharmacistsFaught E. Seizure Classification. Video, slide set, and monograph for: Epilepsy: Outcomes of Therapy. American Pharmaceutical Association, 2000 (Approved for APHA CEU credit).Other publications:Abstracts: available by request to rfaught@emory.eduAmerican Epilepsy Society abstracts 2004-2020 are available at Search on “Faught”Educational material for patients and families:Benbadis SR, Faught E, Green RC. System Overload: A Book about Seizures. Atlanta: Pritchett-Hull, 1998.Faught E. Antiepileptic Drugs, chapter in: Kuzniecky R (ed). Epilepsy 101: The Ultimate Guide for Patients and Families. New York: Medicus Press, 2010 () Faught E. ibid. 2nd edition, 2017Faught E. ibid. 3rd edtition 2020 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download